Swaminathan P. Iyer, M.D.

Peer-Reviewed Articles

1. Allen, PB, Goyal, S, Iyer, SP, Talluru, S, Huen, A, Greenwell, B, Scribner, J, Paulino, D, Speegle, S, Baird, K, Beaven, A, Switchenko, JM, Rangarajan, S, Mehta, A, O'Leary, CB, Case, K, Adams, B, Ayers, AA, Bhatti, S, Krishnasamy, S, Porcu, P, Sethi, T, Foss, FM, Lechowicz, MJ, Rozati, S. Racial differences in mycosis fungoides and Sézary syndrome. Journal of the American Academy of Dermatology 94(2):509-516, 2026. e-Pub 2026. PMID: 41033490.
2. Iyer, SP, Mehta-Shah, N, Advani, RH, Bartlett, NL, Christensen, JH, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, WS, Alpdogan, Ö, Feldman, T, Camus, V, Gritti, G, Zinzani, PL, Belada, D, Mayer, J, Choi, I, Cheong, JW, Rustia, E, Fenton, K, Fanale, MA, Savage, KJ, Horwitz, SM. Association of PET4 response with outcomes of BV-CHP vs CHOP in the ECHELON-2 trial in CD30+ peripheral T-cell lymphoma. Blood Advances 9(23):5976-5987, 2025. e-Pub 2025. PMID: 40829107.
3. Zoref-Lorenz A, Murakami J, Gurion R, Iyer SP, Abadi U, Cohen I, Goyal G, Mohamed S, Nikiforow S, Natour AEH, Weinstein S, Yacobovich J, Cho HL, Raanani P, Nagler A, Berliner N, Daver N, Itchaki G, Izraeli S, Ellis M, Jordan MB. The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma. Blood Adv 9(17):4515-4525, 2025. e-Pub 2025. PMID: 40249910.
4. Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Silva, FR, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma. Nature medicine 31(6):1987-1993, 2025. e-Pub 2025. PMID: 40186077.
5. Long, JP, Prakash, R, Edelkamp, P, Knafl, M, Lionel, AC, Nair, R, Ahmed, S, Strati, P, Malpica Castillo, LE, Al Zaki, A, Chien, KS, Chihara, D, Westin, JR, Khawaja, F, Nastoupil, L, Mulanovich, VE, Futreal, A, Woodman, SE, Daver, N, Flowers, CR, Neelapu, SS, Manzano, JM, Iyer, SP. Cytokine Storms in COVID-19, Hemophagocytic Lymphohistiocytosis, and CAR-T Therapy. JAMA Network Open 8(4), 2025. e-Pub 2025. PMID: 40193078.
6. Iyer, SP, Dakhil, SR, Shinohara, M, Zain, J, Acosta, M, Foss, FM. Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial. Blood Neoplasia 2(1), 2025. e-Pub 2025. PMID: 40546726.
7. Iyer, SP, Dakhil, SR, Shinohara, M, Zain, J, Acosta, M, Foss, FM. Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment. Blood Neoplasia 2(1), 2025. e-Pub 2025. PMID: 40546726.
8. Gaulin C, Jain P, Nair R, Iyer SP, Lee HJ, Fayad L, Feng L, Ok CY, Kanagal-Shamanna R, Oriabure O, Chen W, Xu G, Deswal A, Iliescu C, Badillo M, Ky M, Avellaneda M, Tangc G, Medeiros LJ, Vega F, Flowers CR, Wang ML. Phase 2 trial of ibrutinib in previously untreated high-risk smoldering mantle cell lymphoma. Leuk Lymphoma:1-5, 2025. e-Pub 2025. PMID: 39838574.
9. Torres-Cabala CA, Yescas J, Zhang Y, Huen A, Gaur S, Tefft K, Tang G, Curry JL, Gunther JR, Dabaja BS, Iyer SP, Miranda RN, Choi J, Nardi V. PRIMARY CUTANEOUS CD8+ AGGRESSIVE EPIDERMOTROPIC CYTOTOXIC T-CELL LYMPHOMA WITH NOVEL FGFR1 FUSION TREATED WITH PEMIGATINIB. Blood Adv, 2025. e-Pub 2025. PMID: 39825823.
10. Fang P, Noticewala SS, Wu SY, Gunther JR, Ludmir EB, Medeiros LJ, Strati P, Nair R, Nze C, Nastoupil LJ, Ahmed S, Castillo LM, Fayad L, Westin J, Neelapu S, Flowers C, Huen A, Iyer SP, Dabaja B, Pinnix CC. Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?. Adv Radiat Oncol 9(12):101650, 2024. e-Pub 2024. PMID: 39553398.
11. Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, Hu B, Beitinjaneh A, Weng WK, Kim YH, Khodadoust MS, Huen AO, Williams LM, Ma A, Huang E, Ganpule A, Nagar SD, Sripakdeevong P, Cullingford EL, Karnik S, Dequeant ML, Patel JN, He XS, Li Z, He QA, Mendonez JH, Keegan A, Horwitz SM. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study. Lancet Oncol 26(1):110-122, 2024. e-Pub 2024. PMID: 39617017.
12. Prasad R, Rehman A, Rehman L, Darbaniyan F, Blumenberg V, Schubert ML, Mor U, Zamir E, Schmidt S, Hayase T, Chia-Chi C, McDaniel LK, Flores I, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Wang ML, Jain P, Nastoupil LJ, Westin JR, Arora R, Turner JG, Khawaja F, Wu R, Dennison JB, Menges M, Hidalgo-Vargas M, Reid KM, Davila ML, Dreger P, Korell F, Schmitt A, Tanner MR, Champlin RE, Flowers CR, Shpall EJ, Hanash S, Neelapu SS, Schmitt M, Subklewe M, Fahrmann J, Stein-Thoeringer C, Elinav E, Jain MD, Hayase E, Jenq RR, Saini NY. Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy. Blood 145(8):823-839, 2024. e-Pub 2024. PMID: 39441941.
13. Herrera AF, Zain J, Savage KJ, Feldman T, Brammer JE, Chen L, Puverel S, Popplewell L, Budde LE, Mei M, Hosing C, Nair R, Leslie L, Daniels S, Peters L, Forman S, Rosen S, Kwak L, Iyer SP. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study. Lancet Haematol 11(9):e671-e681, 2024. e-Pub 2024. PMID: 39067464.
14. Khawaja F, Ahmed S, Iyer SP, Sassine J, Handley G, Prakash R, VanWierren T, Jackson J, Zubovskaia A, Ramdial J, Rondon G, Patel KK, Spallone A, Ariza-Heredia EJ, Mulanovich V, Angelidakis G, Jiang Y, Chemaly RF. Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy: An Observational Study With Focus on Oncologic Outcomes. Open Forum Infect Dis 11(8):ofae422, 2024. e-Pub 2024. PMID: 39086466.
15. Bhansali RS, Ellin F, Relander T, Cao M, Li W, Long Q, Ganesan N, Stuver R, Horwitz SM, Wudhikarn K, Hwang SR, Bennani NN, Chavez J, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain JM, Ruiz M, Brammer JE, Prakash R, Iyer SP, Olszewski AJ, Major A, Riedell PA, Smith SM, Goldin C, Haverkos B, Hu B, Zhuang TZ, Allen PB, Toama W, Janakiram M, Brooks TR, Jagadeesh D, Hariharan N, Goodman AM, Hartman G, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas. Blood Adv 8(13):3507-3518, 2024. e-Pub 2024. PMID: 38739715.
16. Wu SY, Damron EP, Xu J, Fang PQ, Dai J, Nair R, Malpica Castillo LE, Fayad LE, Torres-Cabala CA, Medeiros LJ, Vega F, Miranda RN, Duvic M, Pinnix CC, Dabaja BS, Iyer SP, Huen AO, Gunther JR. Radiotherapy in the treatment of primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder. Int J Dermatol, 2024. e-Pub 2024. PMID: 38955474.
17. Gunther JR, Xu J, Bhutani MS, Strati P, Fang PQ, Wu SY, Dabaja BS, Dong W, Bhosale PR, Flowers CR, Nair R, Malpica Castillo L, Fayad L, Iyer SP, Parmer S, Wang M, Lee HJ, Samaniego F, Westin J, Ahmed S, Nze CC, Jain P, Neelapu SS, Rodriguez MA, Chihara D, Nastoupil LJ, Pinnix CC. Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial. Lancet Haematol 11(7):e521-e529, 2024. e-Pub 2024. PMID: 38843856.
18. Lionel AC, Gurumurthi A, Fetooh A, Eldaya R, Ahmed S, Iyer SP, Nastoupil LJ, Westin J, Nair R, Fayad L, Malpica L, Tummala S, Flowers C, Neelapu SS, Wang ML, Jain P. Efficacy and safety of brexucabtagene autoleucel CAR T-cell therapy with BTK inhibitors in the treatment of relapsed mantle cell lymphoma with central nervous system involvement. Leuk Lymphoma 65(5):669-673, 2024. e-Pub 2024. PMID: 38248629.
19. Iyer SP, Johnston PB, Barta SK. Pralatrexate injection combined with CHOP for treatment of PTCL: results from the Fol-CHOP dose-finding phase 1 trial. Blood Adv 8(2):353-364, 2024. e-Pub 2024. PMID: 38029357.
20. Iyer SP, Huen A, Ai WZ, Jagadeesh D, Lechowicz MJ, Okada C, Feldman TA, Ghione P, Alderuccio JP, Champion R, Kim SH, Mohrbacher A, Routhu KV, Barde P, Nair AM, Haverkos BM. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study. Haematologica 109(1):209-219, 2024. e-Pub 2024. PMID: 37439343.
21. Gunther, J, Iyer, SP, Hunt, KK, Fang, H, Wang, S, Clemens, MW, Pinnix, CC. Beyond surgery. Case Reports in Plastic Surgery and Hand Surgery 11(1), 2024. e-Pub 2024. PMID: 39119029.
22. Gunther JR, Iyer SP, Hunt KK, Fang H, Wang SA, Clemens MW, Pinnix CC. Beyond surgery: the proper role and delivery of radiation therapy in the local-regional management of BIA-ALCL. Case Reports Plast Surg Hand Surg 11(1):2389172, 2024. e-Pub 2024. PMID: 39119029.
23. Al-Juhaishi T, Wang Y, Milton DR, Xu-Monette ZY, Jabbour E, Daher M, Im JS, Bashir Q, Iyer SP, Marin D, Olson AL, Popat U, Qazilbash M, Rondon G, Gulbis AM, Champlin RE, Young KH, Khouri IF. Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant. Bone Marrow Transplant 58(9):1000-1007, 2023. e-Pub 2023. PMID: 37198234.
24. Strati, P, Li, X, Deng, Q, Marques-Piubelli, ML, Henderson, J, Watson, G, Deaton, FL, Cain, JT, Yang, H, Ravanmehr, V, Fayad, LE, Iyer, SP, Nastoupil, L, Hagemeister, FB, Parra, ER, Saini, N, Takahashi, K, Fowler, N, Westin, JR, Steiner, RE, Nair, R, Flowers, CR, Wang, L, Ahmed, S, Al-Atrash, G, Vega, F, Neelapu, SS, Green, M. Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNγ-expressing CD8 T cells. Cell Reports Medicine 4(8):101158, 2023. e-Pub 2023. PMID: 37586321.
25. Qiu L, Tang G, Li S, Vega F, Lin P, Wang SA, Wang W, Iyer SP, Malpica L, Miranda RN, Konoplev S, Tang Z, Fang H, Medeiros LJ, Xu J. DUSP22 rearrangement is associated with distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma. Haematologica 108(6):1604-1615, 2023. e-Pub 2023. PMID: 36453104.
26. Nguyen CN, Iyer SP, Duvic M, Barde PJ, Nair A, Routhu KV, Huen AO. Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome. Invest New Drugs 41(2):350-355, 2023. e-Pub 2023. PMID: 37004644.
27. Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, Strati P. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica 108(4):1163-1167, 2023. e-Pub 2023. PMID: 36384251.
28. Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med 29(4):906-916, 2023. e-Pub 2023. PMID: 36914893.
29. Iyer SP. Newer insights on how to TEC down T-ALL. Blood 141(5):444-445, 2023. e-Pub 2023. PMID: 36729545.
30. Westin J, Davis RE, Feng L, Hagemeister F, Steiner R, Lee HJ, Fayad L, Nastoupil L, Ahmed S, Rodriguez A, Fanale M, Samaniego F, Iyer SP, Nair R, Oki Y, Fowler N, Wang M, Ma MCJ, Vega F, McDonnell T, Pinnix C, Griffith D, Lu Y, Tewari S, Sun R, Scott DW, Flowers CR, Neelapu S, Green MR. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma. J Clin Oncol 41(4):JCO2200597, 2023. e-Pub 2023. PMID: 35952327.
31. Gordon LI, Karmali R, Kaplan JB, Popat R, Burris HA, Ferrari S, Madan S, Patel MR, Gritti G, El-Sharkawi D, Chau FI, Radford J, de Oteyza JP, Zinzani PL, Iyer SP, Townsend W, Miao H, Proscurshim I, Wang S, Katyayan S, Yuan Y, Zhu J, Stumpo K, Shou Y, Carpio C, Bosch F. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). Oncotarget 14(1):57-70, 2023. e-Pub 2023. PMID: 36702329.
32. Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash S. A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma. Cell Rep Med 3(11):100720, 2022. e-Pub 2022. PMID: 36384092.
33. Strati P, Jallouk AP, Sun R, Choi J, Das K, Cherng HJ, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Steiner RE, Huff CD, Yu Y, Mistry H, Pulsifer B, Noorani M, Saini N, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Hildebrandt MAT, Neelapu SS. Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy. Leukemia 36(11):2669-2677, 2022. e-Pub 2022. PMID: 36127509.
34. Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen SLS, Zinzani PL, Truemper LH, Illidge TM, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer SP. Role of Stem Cell Transplant in CD30-positive PTCL following Frontline Brentuximab Vedotin+CHP or CHOP in ECHELON-2. Blood Adv 6(19):5550-5555, 2022. e-Pub 2022. PMID: 35470385.
35. Saini NY, Swoboda DM, Greenbaum U, Ma J, Patel RD, Devashish K, Das K, Tanner MR, Strati P, Nair R, Fayad L, Ahmed S, Lee HJ, Iyer SP, Steiner R, Jain N, Nastoupil L, Loghavi S, Tang G, Bassett RL, Jain P, Wang M, Westin JR, Green MR, Sallman DA, Padron E, Davila ML, Locke FL, Champlin RE, Garcia-Manero G, Shpall EJ, Kebriaei P, Flowers CR, Jain MD, Wang F, Futreal AP, Gillis N, Neelapu SS, Takahashi K. Clonal hematopoiesis is associated with increased risk of severe neurotoxicity in axicabtagene ciloleucel therapy of large B-cell lymphoma. Blood Cancer Discov 3(5):385-393, 2022. e-Pub 2022. PMID: 35533245.
36. Forero-Torres, A, Chandler, JC, Iyer, SP, Kanate, AS, Quinlan, M, Hoever, P, Izquierdo, MA, Davis, J, Madan, S. Phase 1 Study Evaluating Pharmacokinetics and Tolerability of Ofatumumab Combined With Bendamustine in Patients With Indolent B-Cell Non-Hodgkin's Lymphoma. Clinical Pharmacology in Drug Development 11(9):1099-1109, 2022. e-Pub 2022. PMID: 35819310.
37. Cherng HJ, Sun R, Sugg B, Irwin R, Yang H, Le CC, Deng Q, Fayad L, Fowler NH, Parmar S, Steiner R, Hagemeister F, Nair R, Lee HJ, Rodriguez M, Samaniego F, Iyer SP, Flowers CR, Wang L, Nastoupil LJ, Neelapu SS, Ahmed S, Strati P, Green MR, Westin J. Risk assessment with low pass whole genome sequencing of cell free DNA before CD19 CAR T-cells for large B-cell lymphoma. Blood 140(5):504-515, 2022. e-Pub 2022. PMID: 35512184.
38. Marques-Piubelli ML, Sagert J, Pham MT, Will M, Henderson D, Tipton K, Iyer S, Lu W, Khan KB, Hamana L, Chapman JR, Thakral B, Xu J, Miranda RN, Jennings K, Solis LM, Vega F. CD70 is a Potential Target Biomarker in Peripheral T-cell Lymphomas. Histopathology 81(2):272-275, 2022. e-Pub 2022. PMID: 35474464.
39. Han G, Deng Q, Marques-Piubelli ML, Dai E, Dang M, Ma MCJ, Li X, Yang H, Henderson J, Kudryashova O, Meerson M, Isaev S, Kotlov N, Nomie KJ, Bagaev A, Parra ER, Solis Soto LM, Parmar S, Hagemeister FB, Ahmed S, Iyer SP, Samaniego F, Steiner R, Fayad L, Lee H, Fowler NH, Flowers CR, Strati P, Westin JR, Neelapu SS, Nastoupil LJ, Vega F, Wang L, Green MR. Follicular lymphoma microenvironment characteristics associated with tumor cell mutations and MHC class II expression. Blood Cancer Discov. e-Pub 2022. PMID: 35687817.
40. Sanjay S, Leo SW, Au Eong KG, Adriono GA, Fong KC, Anand K, Kadarisman RS, Granet DB, Mahendradas P, Shetty R, Souza SD, Iyer SP. Global Ophthalmology Practice Patterns during COVID-19 Pandemic and Lockdown. Ophthalmic Epidemiol 29(3):1-12, 2022. e-Pub 2022. PMID: 34167454.
41. Al Zaki A, Feng L, Watson G, Ahmed SA, Mistry H, Nastoupil LJ, Hawkins M, Nair R, Iyer SP, Lee HJ, Steiner RE, Flowers CR, Shpall EJ, Kebriaei P, Neelapu SS, Westin JR, Strati P. Day 30 SUVmax Predicts Progression in Lymphoma Patients Achieving PR/SD After CAR T-cell Therapy. Blood Adv 6(9):2867-2871, 2022. e-Pub 2022. PMID: 35015825.
42. Akin S, Hosing C, Khouri I, Ahmed S, Alousi A, Fowler N, Joseph J, Truxillo J, Ramdial JL, Maadani F, Rondon G, Daher M, Im JS, Steiner R, Westin J, Iyer SP, Dabaja B, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall E, Champlin RE, Nieto Y, Srour SA. Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement. Blood Adv 6(7):2267-2274, 2022. e-Pub 2022. PMID: 35008100.
43. Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica 107(4):899-908, 2022. e-Pub 2022. PMID: 33951890.
44. Horwitz, SM, O'Connor, O, Pro, B, Trümper, L, Iyer, SP, Advani, RH, Bartlett, NL, Christensen, JH, Morschhauser, F, Domingo-Domenech, E, Rossi, G, Kim, WS, Feldman, T, Menne, T, Belada, D, Illés, Á, Tobinai, K, Tsukasaki, K, Yeh, S, Shustov, AR, Hüttmann, A, Savage, KJ, Yuen, S, Zinzani, PL, Miao, H, Bunn, V, Fenton, K, Fanale, MA, Puhlmann, M, Illidge, TM. The ECHELON-2 Trial. Annals of Oncology 33(3):288-298, 2022. e-Pub 2022. PMID: 34921960.
45. Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M, Research Group MC, Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (=65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet Oncol 23(3):406-415, 2022. e-Pub 2022. PMID: 35074072.
46. Khanlari M, Li S, Miranda RN, Iyer S, Konoplev S, Lin P, Yin CC, Tang G, Qiu L, Vega F, Medeiros LJ, Xu J. Small cell/lymphohistiocytic morphology is associated with peripheral blood involvement, CD8 positivity and retained T-cell antigens, but not outcome in adults with ALK+ anaplastic large cell lymphoma. Mod Pathol 35(3):412-418, 2022. e-Pub 2022. PMID: 34628481.
47. Zoref-Lorenz A, Murakami J, Hofstetter L, Iyer S, Alotaibi AS, Mohamed SF, Miller PG, Guber E, Weinstein S, Yacobovich J, Nikiforow S, Ebert BL, Lane A, Pasvolsky O, Raanani P, Nagler A, Berliner N, Daver N, Ellis M, Jordan MB. An improved index for diagnosis and mortality prediction in malignancy associated hemophagocytic lymphohistiocytosis. Blood 139(7):1098-1110, 2022. e-Pub 2022. PMID: 34780598.
48. Krishnan M, Bociek RG, Fanale M, Iyer SP, Lechowicz MJ, Bierman PJ, Armitage JO, Lunning M, Kallam A, Vose JM. Phase 1 trial of carfilzomib in relapsed/refractory peripheral T-cell lymphoma. Ann Hematol 101(2):335-340, 2022. e-Pub 2022. PMID: 34668982.
49. Kwaramba, T, Lewis, B, Burks, B, Ruiz, B, Iyer, SP, Safa, F. Sustained response to erythropoietin for anemia in NK-cell large granular lymphocytosis. Leukemia Research Reports 17, 2022. e-Pub 2022. PMID: 35242524.
50. Tevis SE, Hunt KK, Miranda RN, Lange C, Pinnix CC, Iyer S, Butler CE, Clemens MW. Breast Implant-associated Anaplastic Large Cell Lymphoma: A Prospective Series of 52 Patients. Ann Surg 275(1):e245-e249, 2022. e-Pub 2022. PMID: 32568749.
51. Qiu L, Medeiros LJ, Tang G, Khanlari M, Li S, Konoplev S, Wang SA, Yin CC, Khoury JD, Wang W, Miranda RN, Iyer S, You MJ, Xu J. The Leukemic Phase of ALK-Negative Anaplastic Large Cell Lymphoma Is Associated with CD7 Positivity, Complex Karyotype, TP53 Deletion, and a Poor Prognosis. Cancers (Basel) 13(24), 2021. e-Pub 2021. PMID: 34944936.
52. Evans MG, Medeiros LJ, Marques-Piubelli ML, Wang HY, Ortiz-Hidalgo C, Pina-Oviedo S, Morine A, Clemens MW, Hunt KK, Iyer S, Hu Q, Recavarren C, Demichelis R, Romero M, Sohani AR, Misialek M, Amin MB, Bueso-Ramos CE, Carballo-Zarate AA, Lee HJ, Ok CY, Xu J, Miranda RN. Breast implant-associated anaplastic large cell lymphoma: clinical follow-up and analysis of sequential pathologic specimens of untreated patients shows persistent or progressive disease. Mod Pathol 34(12):2148-2153, 2021. e-Pub 2021. PMID: 34155351.
53. Medeiros LJ, Marques-Piubelli ML, Sangiorgio VFI, Ruiz-Cordero R, Vega F, Feldman AL, Chapman JR, Clemens MW, Hunt KK, Evans MG, Khoo C, Lade S, Silberman M, Morkowski J, Pina EM, Mills DC, Bates CM, Magno WB, Sohani AR, Sieling BA, O'Donoghue JM, Bacon CM, Patani N, Televantou D, Turner SD, Johnson L, MacNeill F, Wotherspoon AC, Iyer SP, Malpica LE, Patel KP, Xu J, Miranda RN. Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship. Mod Pathol 34(12):2154-2167, 2021. e-Pub 2021. PMID: 34226673.
54. Nguyen CN, Iyer SP, Miranda RN, Torres-Cabala CA, Curry JL, Fang P, Thomas VD, Huen AO. Aggressive primary cutaneous anaplastic large cell lymphoma with massive bilateral upper limb involvement at relapse. JAAD Case Rep 17:34-37, 2021. e-Pub 2021. PMID: 34692965.
55. Khouri IF, Milton DR, Gulbis AM, Jabbour EJ, Nastoupil L, Ledesma C, Anderlini P, Bashir Q, Daher M, Im JS, Iyer SP, Marin D, Mehta RS, Olson AL, Popat UR, Qazilbash M, Saini N, Samaniego F, Rondon G, Medeiros LJ, Champlin RE. Nine-Year Follow-up of Patients with Relapsed Follicular Lymphoma after Nonmyeloablative Allogeneic Stem Cell Transplant and Autologous Transplant. Clin Cancer Res 27(21):5847-5856, 2021. e-Pub 2021. PMID: 34380640.
56. Landsburg DJ, Barta SK, Ramchandren R, Batlevi C, Iyer S, Kelly K, Micallef IN, Smith SM, Stevens DA, Alvarez M, Califano A, Shen Y, Bosker G, Parker J, Soikes R, Martinez E, von Roemeling R, Martell RE, Oki Y. Fimepinostat (CUDC-907) in patients with relapsed/refractory diffuse large B cell and high-grade B-cell lymphoma: report of a phase 2 trial and exploratory biomarker analyses. Br J Haematol 195(2):201-209, 2021. e-Pub 2021. PMID: 34341990.
57. Marques-Piubelli ML, Solis LM, Parra ER, Castillo LM, Gouni S, Nair R, Chihara D, Konopleva M, Wistuba II, Iyer SP, Vega F, Strati P. BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified. Blood Cancer J 11(9):153, 2021. e-Pub 2021. PMID: 34531377.
58. Subbiah, V, Kuravi, S, Ganguly, S, Welch, DR, Foster, CJ, Mushtaq, MU, Hegde, A, Iyer, SP, Amini, B, Ali, SM, Madison, RW, Venstrom, JM, Jensen, R, McGuirk, J, Amin, H, Balusu, R. Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. ESMO Open 6(4), 2021. e-Pub 2021. PMID: 34242968.
59. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. e-Pub 2021. PMID: 34264268.
60. Strati P, Ahmed S, Furqan F, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Horowitz SB, Feng L, Sun R, Claussen CM, Hawkins MC, Johnson NA, Singh P, Mistry H, Johncy S, Adkins S, Kebriaei P, Shpall EJ, Green MR, Flowers CR, Westin J, Neelapu SS. Prognostic Impact of Corticosteroids on Efficacy of Chimeric Antigen Receptor T-cell Therapy in Large B-cell Lymphoma. Blood 137(23):3272-3276, 2021. e-Pub 2021. PMID: 33534891.
61. Augustyn A, Medeiros LJ, Ludmir EB, Gunther J, Fang P, Li S, Ok CY, Bankston ME, Verma V, Pasalic D, Ahmed S, Nastoupil LJ, Westin JR, Strati P, Neelapu SS, Nair R, Steiner RE, Iyer SP, Rodriguez A, Fayad LE, Flowers CR, Dabaja BS, Pinnix CC. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. Leuk Lymphoma 62(6):1-12, 2021. e-Pub 2021. PMID: 33480830.
62. Mamlouk O, Nair R, Iyer SP, Edwards A, Neelapu SS, Steiner RE, Adkins SA, Hawkins M, Saini N, Devashish K, Strati P, Mandayam S, Ahmed S. Safety of CAR T-cell therapy in kidney transplant recipients. Blood 137(18):2558-2562, 2021. e-Pub 2021. PMID: 33512386.
63. Kunacheewa C, Feng L, Manasanch EE, Bashir Q, Patel KK, Mehta R, Kaufman GP, Srour S, Saini N, Iyer SP, Thomas SK, Weber DM, Orlowski RZ, Qazilbash MH, Lee HC. Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy. Br J Haematol 193(3):e23-e26, 2021. e-Pub 2021. PMID: 33748943.
64. Youssef JG, Zahiruddin F, Youssef G, Padmanabhan S, Ensor J, Pingali SR, Zu Y, Sahay S, Iyer SP. G6PD deficiency and severity of COVID19 pneumonia and acute respiratory distress syndrome: tip of the iceberg?. Ann Hematol 100(3):667-673, 2021. e-Pub 2021. PMID: 33439304.
65. Lyapichev KA, Tang G, Li S, You MJ, Cheng TJ, Miranda RN, Iyer S, Yin CC, Konoplev S, Bueso-Ramos C, Vega F, Medeiros LJ, Xu J. MYC expression is associated with older age, common morphology, increased MYC copy number, and poorer prognosis in patients with ALK+ anaplastic large cell lymphoma. Hum Pathol 108:22-31, 2021. e-Pub 2021. PMID: 33221344.
66. Khanlari M, Tang G, Hao S, Gong Y, Li S, Miranda RN, Lin P, Iyer S, Yin CC, Xie W, Vega F, Medeiros LJ, Xu J. Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma with MYC rearrangement. Br J Haematol 192(1):e17-e21, 2021. e-Pub 2021. PMID: 33216956.
67. Duke TC, Nair R, Torres-Cabala C, Amaria RN, Keiser E, Miranda R, Iyer SP, Heberton M. Angioimmunoblastic T-cell lymphoma associated with immune checkpoint inhibitor treatment. JAAD Case Rep 6(12):1264-1267, 2020. e-Pub 2020. PMID: 33294560.
68. Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP, Weber DM, Berkova Z, Flowers CR, Orlowski RZ, Patel KK. SARS-CoV-2 in multiple myeloma: initial observation and management. Leuk Lymphoma 61(11):2763-2766, 2020. e-Pub 2020. PMID: 33167721.
69. Pinnix CC, Gunther JR, Fang P, Bankston ME, Milgrom SA, Boyce D, Lee HJ, Nair R, Steiner R, Strati P, Ahmed S, Iyer SP, Westin J, Parmar S, Rodriguez MA, Nastoupil L, Neelapu S, Flowers C, Dabaja BS. Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. JAMA Netw Open 3(9):e2013935, 2020. e-Pub 2020. PMID: 32990738.
70. Strati P, Nastoupil LJ, Westin J, Fayad LE, Ahmed S, Fowler NH, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Adkins S, Claussen CM, Martinez CS, Hawkins MC, Johnson NA, Singh P, Mistry HE, Horowitz S, George S, Feng L, Kebriaei P, Shpall EJ, Neelapu SS, Tummala S, Chi TL. Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv 4(16):3943-3951, 2020. e-Pub 2020. PMID: 32822484.
71. Huen A, Haverkos BM, Zain J, Radhakrishnan R, Lechowicz MJ, Devata S, Korman NJ, Pinter-Brown L, Oki Y, Barde PJ, Nair A, Routhu KV, Viswanadha S, Vakkalanka S, Iyer SP. Phase I/Ib Study of Tenalisib (RP6530), a Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. Cancers (Basel) 12(8), 2020. e-Pub 2020. PMID: 32824175.
72. Glober G, Gunther J, Fang P, Milgrom S, Korivi BR, Jensen CT, Wagner-Bartak NA, Ahmed S, Lee HJ, Nair R, Steiner R, Parmar S, Iyer S, Westin J, Fayad L, Rodriguez MA, Neelapu S, Nastoupil L, Flowers CR, Dabaja BS, Pinnix CC. Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. Clin Lymphoma Myeloma Leuk 20(8):533-541, 2020. e-Pub 2020. PMID: 32291233.
73. Anand K, Sahu G, Burns E, Ensor A, Ensor J, Pingali SR, Subbiah V, Iyer SP. Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. ESMO Open 5(4), 2020. e-Pub 2020. PMID: 32817069.
74. Gordon, LI, Kaplan, JB, Popat, R, Burris, H, Ferrari, S, Madan, S, Patel, MR, Gritti, G, El-Sharkawi, D, Chau, I, Radford, J, De Oteiza, JP, Zinzani, PL, Iyer, SP, Townsend, W, Karmali, R, Miao, H, Proscurshim, I, Wang, S, Wu, Y, Stumpo, K, Shou, Y, Carpio, C, Bosch, F. Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma A C. Clinical Cancer Research 26(14):3546-3556, 2020. e-Pub 2020. PMID: 32327472.
75. Pinnix CC, Gunther JR, Dabaja BS, Strati P, Fang P, Hawkins MC, Adkins S, Westin J, Ahmed S, Fayad L, Lee HJ, Nair R, Steiner RE, Iyer SP, Rodriguez MA, Wang M, Flowers C, Neelapu SS, Nastoupil LJ. Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma. Blood Adv 4(13):2871-2883, 2020. e-Pub 2020. PMID: 32589728.
76. Wang, ES, Aplenc, R, Chirnomas, D, Dugan, M, Fazal, S, Iyer, SP, Lin, TL, Nand, S, Pierce, K, Shami, PJ, Vermette, JJ, Abboud, CN. Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma 61(8):1965-1973, 2020. e-Pub 2020. PMID: 32432489.
77. Elhammali A, Amini B, Ludmir EB, Gunther JR, Milgrom SA, Pinnix CC, Andraos T, Yoder A, Weber D, Orlowski R, Manasanch E, Patel K, Strati P, Nair R, Lee HC, Thomas S, Iyer S, Kaufmann G, Garg N, Dabaja BS. New Paradigm for Radiation in Multiple Myeloma: lower yet effective dose to avoid radiation toxicity. Haematologica 105(7):e355-e357, 2020. e-Pub 2020. PMID: 31919088.
78. Sathyanarayanan V, Flowers CR, Iyer SP. Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States. JCO Glob Oncol 6:1124-1133, 2020. e-Pub 2020. PMID: 32692628.
79. Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, Yao Y, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F, Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J, Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G, Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol 95(6):623-629, 2020. e-Pub 2020. PMID: 32239765.
80. Strati P, Ahmed MA, Nastoupil LJ, Feng L, Hagemeister FB, Fayad LE, Rodriguez MA, Samaniego F, Wang M, Westin JR, Lee HJ, Iyer SP, Parmar S, Ahmed S, Nair R, Steiner RE, Noorani M, Flowers CR, Davis RE, Fowler NH, Neelapu SS. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL. Leuk Lymphoma 61(6):1-8, 2020. e-Pub 2020. PMID: 31971032.
81. Babiker HM, Milhem M, Aisner J, Edenfield W, Shepard D, Savona M, Iyer S, Abdelrahim M, Beach CL, Skikne B, Laille E, Tsai KT, Ho T. Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer Chemother Pharmacol 85(5):1009-1010, 2020. e-Pub 2020. PMID: 32215699.
82. Shen J, Medeiros LJ, Li S, Wang SA, Lin P, Khanlari M, Iyer SP, Yin CC, Tang G, Jorgensen JL, Hu S, Miranda RN, Xu J. CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma. Hum Pathol 98:1-9, 2020. e-Pub 2020. PMID: 32032618.
83. Varma, A, Sui, D, Milton, D, Tang, G, Saini, N, Hasan, O, Mukherjee, A, Joseph, JJ, Bashir, Q, Rondon, G, Srour, S, Popat, UR, Hosing, C, Nieto, Y, Kebriaei, P, Alousi, AM, Ahmed, S, Mehta, RS, Khouri, IF, Ahmed, H, Iyer, SP, Weber, DM, Thomas, SK, Manasanch, EE, Lee, HC, Patel, K, Ciurea, SO, Shpall, E, Orlowski, R, Champlin, RE, Qazilbash, MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
84. Jain P, Zhang S, Kanagal-Shamanna R, Ok CY, Nomie K, Gonzalez GN, Gonzalez-Pagan O, Hill HA, Lee HJ, Fayad L, Westin J, Nastoupil L, Hagemeister F, Chen W, Oriabure O, Badillo M, Jiang C, Yixin Y, Li S, Tang G, Yin CC, Patel KP, Medeiros LJ, Nair R, Ahmed S, Iyer SP, Thirumurthi S, Champlin R, Xu G, Tinsu P, Santos D, Wang R, Han G, Zhang J, Song X, Neelapu S, Romaguera J, Futreal A, Flowers C, Fowler N, Wang L, Wang ML. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 4(6):1038-1050, 2020. e-Pub 2020. PMID: 32191807.
85. Akdeniz Dogan Z, Miranda RN, Iyer S, Steiner RE, Singh P, Clemens MW. Anaplastic Large Cell Lymphoma of the Breast Arising in a Burn Cicatrix. Aesthet Surg J 40(4):NP159-NP163, 2020. e-Pub 2020. PMID: 31495882.
86. Iyer, SP. Demand and supply of face masks during the COVID-19 pandemic. Smart and Sustainable Manufacturing Systems 4(3), 2020. e-Pub 2020.
87. Babiker, HM, Milhem, M, Aisner, J, Edenfield, WJ, Shepard, D, Savona, MR, Iyer, SP, Abdelrahim, M, Beach, CL, Skikne, B, Laille, E, Tsai, KT, Ho, TH. Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancer. Cancer chemotherapy and pharmacology 85(3):621-626, 2020. e-Pub 2020. PMID: 32036412.
88. Shen J, Li S, Medeiros LJ, Lin P, Wang SA, Tang G, Yin CC, You MJ, Khoury JD, Iyer SP, Miranda RN, Xu J. PD-L1 expression is associated with ALK positivity and STAT3 activation, but not outcome in patients with systemic anaplastic large cell lymphoma. Mod Pathol 33(3):324-333, 2020. e-Pub 2020. PMID: 31383967.
89. Anand K, Ensor J, Pingali SR, Hwu P, Duvic M, Chiang S, Miranda R, Zu Y, Iyer S. T-cell lymphoma secondary to checkpoint inhibitor therapy. J Immunother Cancer 8(1), 2020. e-Pub 2020. PMID: 32114498.
90. Lyapichev KA, Sukswai N, Strati P, Iyer SP, Medeiros LJ, Miranda RN. Unicentric Castleman disease, hyaline vascular variant, stromal rich, with increased plasma cells and a high level of serum IL-6: Raising the diagnostic and therapeutic issues. Ann Diagn Pathol 43:151398, 2019. e-Pub 2019. PMID: 31630065.
91. Saini, N, Ma, J, Milton, D, Patel, R, Varma, A, Bashir, Q, Delgado, R, Mukherjee, A, Rondon, G, Popat, UR, Hosing, C, Nieto, Y, Kebriaei, P, Alousi, AM, Ahmed, S, Tang, G, Mehta, RS, Srour, S, Khouri, IF, Iyer, SP, Weber, DM, Thomas, SK, Lee, HC, Manasanch, EE, Patel, K, Orlowski, R, Champlin, RE, Qazilbash, MH. Impact of autologous transplantation in patients with multiple myeloma with t(11;14). Clinical Cancer Research 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
92. Flinn, IW, Gribben, JG, Dyer, MJ, Wierda, WG, Maris, MB, Furman, RR, Hillmen, P, Rogers, KA, Iyer, SP, Quillet-Mary, A, Ysebaert, L, Walter, HS, Verdugo, M, Klein, C, Huang, H, Jiang, Y, Lozanski, G, Pignataro, DS, Humphrey, K, Mobasher, M, Kipps, TJ. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood 133(26):2765-2775, 2019. e-Pub 2019. PMID: 30862645.
93. Pinnix CC, Milgrom SA, Cheah CY, Gunther JR, Ludmir EB, Wogan CF, Nastoupil LJ, Neelapu SS, Westin J, Lee HJ, Iyer SP, Steiner RE, Fayad LE, Fowler NH, Wang ML, Samaniego F, Rodriguez MA, Rich AE, Medeiros LJ, Dabaja BS. Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. Blood Adv 3(9):1356-1367, 2019. e-Pub 2019. PMID: 31036721.
94. Forero-Torres, A, Ramchandren, R, Yacoub, A, Wertheim, MS, Edenfield, WJ, Caimi, PF, Gutierrez, M, Akard, LP, Escobar, C, Call, J, Persky, DO, Iyer, SP, DeMarini, DJ, Zhou, L, Chen, X, Dawkins, F, Phillips, T. Parsaclisib, a potent and highly selective PI3Kd inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood 133(16):1742-1752, 2019. e-Pub 2019. PMID: 30803990.
95. Mahajan M, Naik N, Jain K, Patira N, Prasad S, Mogri S, Muwonge R, Lucas E, Faruq F, Sankaranarayanan R, Iyer S, Basu P. Study of Knowledge, Attitudes, and Practices Toward Risk Factors and Early Detection of Noncommunicable Diseases Among Rural Women in India. J Glob Oncol 5:1-10, 2019. e-Pub 2019. PMID: 30998427.
96. Tran J, Vickers A, Ponce CP, Iyer SP, Lee AG. Triple-hit lymphoma of the cavernous sinus. Can J Ophthalmol 54(2):e61-e66, 2019. e-Pub 2019. PMID: 30975363.
97. Anand K, Kumar P, Pingali SR, Pati D, Iyer SP. Acute myeloid leukemia with eosinophilia after cyclin-dependent kinases 4/6 inhibitor treatment due to underlying clonal hematopoiesis of indeterminate potential. Am J Hematol 94(3):E82-E85, 2019. e-Pub 2019. PMID: 30575100.
98. Collins MS, Miranda RN, Medeiros LJ, Silva de Meneses MP, Iyer SP, Butler CE, Liu J, Clemens MW. Characteristics and Treatment of Advanced Breast Implant-Associated Anaplastic Large Cell Lymphoma. Plast Reconstr Surg 143(3S A Review of Breast Implant-Associated Anaplastic Large Cell L):41S-50S, 2019. e-Pub 2019. PMID: 30817555.
99. Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Á I, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L, Group ES. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393(10168):229-240, 2019. e-Pub 2019. PMID: 30522922.
100. Ma H, Padmanabhan Iyer S, Parmar S, Gong Y. Adoptive cell therapy for acute myeloid leukemia. Leuk Lymphoma:1-11. e-Pub 2019. PMID: 30628504.
101. Basu P, Mahajan M, Patira N, Prasad S, Mogri S, Muwonge R, Lucas E, Sankaranarayanan R, Iyer S, Naik N, Jain K. A pilot study to evaluate home-based screening for the common non-communicable diseases by a dedicated cadre of community health workers in a rural setting in India. BMC Public Health 19(1):14, 2019. e-Pub 2019. PMID: 30606132.
102. Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk 19(1):e51-e61, 2019. e-Pub 2019. PMID: 30360985.
103. Flinn IW, Gribben JG, Dyer MJ, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, SP &I, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, J Kipps MMAT. Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood, 2019. e-Pub 2019.
104. Anand K, Pingali SR, Trachtenberg B, Iyer SP. Complete Response to R-EPOCH in Primary Cardiac Lymphoma. Case Rep Hematol 2019:7690430, 2019. e-Pub 2019. PMID: 31214365.
105. Qin Q, Nan X, Miller T, Fisher R, Teh B, Pandita S, Farach AM, Pingali SR, Pandita RK, Butler EB, Pandita TK, Iyer SP. Complete Local and Abscopal Responses from a Combination of Radiation and Nivolumab in Refractory Hodgkin's Lymphoma. Radiat Res 190(3):322-329, 2018. e-Pub 2018. PMID: 29949442.
106. Kelly KR, Friedberg JW, Park SI, McDonagh KT, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen PJ, Padmanabhan Iyer S, Stefanovic A, Bernstein SH, Weitman S, Karnad AB, Monohan G, VanderWalde A, Mena R, Schmelz M, Spier C, Groshen S, Venkatakrishnan K, Zhou X, Sheldon-Waniga E, Leonard EJ, Mahadevan D. Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/vincristine in Relapsed/refractory Aggressive B-cell Lymphoma. Clin Cancer Res. e-Pub 2018. PMID: 30082475.
107. Chakraborty S, Pandita RK, Hambarde S, Mattoo AR, Charaka V, Ahmed KM, Iyer SP, Hunt CR, Pandita TK. SMARCAD1 Phosphorylation and Ubiquitination Are Required for Resection during DNA Double-Strand Break Repair. iScience 2:123-135, 2018. e-Pub 2018. PMID: 29888761.
108. Sun K, Kasparian S, Iyer S, Pingali SR. Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib. Ecancermedicalscience 12:836, 2018. e-Pub 2018. PMID: 29910833.
109. Sun K, Sanchez CG, Pingali SR, Iyer S. Use of PEG-asparaginase in a case of Hepatosplenic γδ T-cell lymphoma with long-term remission after stem cell transplantation. Ecancermedicalscience 12:872, 2018. e-Pub 2018. PMID: 30483352.
110. Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Iyer SP, Shustov AR, Wolfson J, Balser BE, Coiffier B. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma. Hematol Oncol 35(4):914-917, 2017. e-Pub 2017. PMID: 27402335.
111. Nan X, Qin Q, Gentille C, Ensor J, Leveque C, Pingali SR, Phan AT, Rice L, Iyer S. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary center. Leuk Lymphoma 58(9):1-11, 2017. e-Pub 2017. PMID: 28140714.
112. Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan-Iyer S, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Wierda WG, Investigators HS. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leuk Lymphoma 58(2):348-356, 2017. e-Pub 2017. PMID: 27389174.
113. Huang, XJ, Liu, KY, Ritchie, DS, Andersson, BS, Lu, J, Hou, J, Burguera, AF, Wang, J, Yeoh, AJ, Yan, CH, Zhou, DB, Tan, D, Kim, DW, Wu, D, Shpall, E, Kornblau, SM, Neelapu, SS, Hongeng, S, Li, J, Hu, J, Zhang, LS, Wang, L, Malhotra, P, Jiang, Q, Qin, Y, Wong, R, Champlin, RE, Hagemeister, FB, Westin, JR, Iyer, SP, Mathews, V, Wang, Y, Hu, Y, Xiao, Z, Shao, Z, Orlowski, R, Chim, CS, Mulligan, SP, Sanz, M, Ozawa, K, Parmar, S, Issaragrisil, S. Hematology oncology practice in the Asia-Pacific APHCON survey results from the 6th international hematologic malignancies conference. Oncotarget 8(25):41620-41630, 2017. e-Pub 2017. PMID: 28404929.
114. Gentille C, Qin Q, Barbieri A, Ravi PS, S I. Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges. Ecancermedicalscience 11:771, 2017. e-Pub 2017. PMID: 29062389.
115. Lu J, Hou J, Liu KY, Parmar S, De La Fuente A, Andersson B, Yan C, Zhou D, Tan D, Ritchie D, Wu D, Shpall E, Laport GG, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Issaragrisil S, Iyer S, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Rosengarten R, Steuernagle J, Xiao JH, Orlowski R, Chim CS. Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma 57(7):1534-8, 2016. e-Pub 2016. PMID: 26887657.
116. Wen J, Tao W, Hao S, Iyer SP, Zu Y. A unique aptamer-drug conjugate for targeted therapy of multiple myeloma. Leukemia 30(4):987-91, 2016. e-Pub 2016. PMID: 26242462.
117. Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, Padmanabhan Iyer S, Sahin D, Chai A, Fingerle-Rowson G, Press OW. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol 33(30):3467-74, 2015. e-Pub 2015. PMID: 26282650.
118. Zhao N, Pei SN, Qi J, Zeng Z, Iyer SP, Lin P, Tung CH, Zu Y. Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. Biomaterials 67:42-51, 2015. e-Pub 2015. PMID: 26204224.
119. Österborg A, Jewell RC, Padmanabhan-Iyer S, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmen P, Trnêný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Wierda WG, Investigators HS. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica 100(8):e311-4, 2015. e-Pub 2015. PMID: 25769539.
120. Fiskus, WC, Sharma, S, Saha, S, Shah, B, Devaraj, SG, Sun, B, Horrigan, SK, Leveque, CM, Zu, Y, Iyer, SP, Bhalla, K. Pre-clinical efficacy of combined therapy with novel β-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia 29(6):1267-1278, 2015. e-Pub 2015. PMID: 25482131.
121. Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, Iyer SP, Shustov A, Nichols J, Balser J, Balser B, Pro B. Utility of ¹8fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26(4):774-9, 2015. e-Pub 2015. PMID: 25605745.
122. Iyer SP, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 167(3):366-75, 2014. e-Pub 2014. PMID: 25139740.
123. Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther 13(5):1142-54, 2014. e-Pub 2014. PMID: 24435446.
124. Bansal H, Yihua Q, Iyer SP, Ganapathy S, Proia DA, Proia D, Penalva LO, Uren PJ, Suresh U, Carew JS, Karnad AB, Weitman S, Tomlinson GE, Rao MK, Kornblau SM, Bansal S. WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia 28(5):1171-4, 2014. e-Pub 2014. PMID: 24413322.
125. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol 7:11, 2014. e-Pub 2014. PMID: 24456586.
126. Coiffier B, Radford J, Bosly A, Martinelli G, Verhoef G, Barca G, Davies A, Decaudin D, Gallop-Evans E, Padmanabhan-Iyer S, Van Eygen K, Wu KL, Gupta IV, Lin TS, Goldstein N, Jewell RC, Winter P, Lisby S, investigators 4S. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Haematol 163(3):334-42, 2013. e-Pub 2013. PMID: 24032456.
127. Gojo I, Sadowska M, Walker A, Feldman EJ, Iyer SP, Baer MR, Sausville EA, Lapidus RG, Zhang D, Zhu Y, Jou YM, Poon J, Small K, Bannerji R. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol 72(4):897-908, 2013. e-Pub 2013. PMID: 23949430.
128. Nemunaitis J, Mita A, Stephenson J, Mita MM, Sarantopoulos J, Padmanabhan-Iyer S, Nanda N, Gleich L, Benichou AC, Craig A. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemother Pharmacol 71(1):35-41, 2013. e-Pub 2013. PMID: 23053254.
129. Bansal H, Seifert T, Bachier C, Rao M, Tomlinson G, Iyer SP, Bansal S. The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xL. J Biol Chem 287(39):32875-80, 2012. e-Pub 2012. PMID: 22898820.
130. Parmar S, Iyer SP. Bridging the gap in hematological malignancies. Expert Rev Hematol 5(3):257-9, 2012. e-Pub 2012. PMID: 22780206.
131. Ghobrial, IM, Xie, W, Iyer, SP, Badros, AZ, Rourke, M, Leduc, R, Chuma, S, Kunsman, J, Warren, D, Poon, T, Harris, B, Sam, A, Anderson, KC, Richardson, PG, Treon, SP, Weller, EA, Matous, JV. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. American journal of hematology 85(9):670-674, 2010. e-Pub 2010. PMID: 20652865.
132. Yao, S, McCarthy, P, Dunford, LM, Roy, DM, Brown, K, Paplham, P, Syta, M, Lamonica, D, Smiley, S, Battiwalla, M, Iyer, SP, Hahn, T. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Bone marrow transplantation 41(4):393-398, 2008. e-Pub 2008. PMID: 17994116.
133. Cejas PJ, Carlson LM, Zhang J, S P, Kolonias D, Lindner I, Haley S, Boise LH, Lee KP. Protein kinase C betaII plays an essential role in dendritic cell differentiation and autoregulates its own expression. J Biol Chem 280(31):28412-23, 2005. e-Pub 2005. PMID: 15917249.
134. Gordon, MJ, Duan, Z, Zhao, H, Nastoupil, L, Ng, S, Danilov, AV, Iyer, SP, Giordano, SH. Influence of treatment intensity and medical comorbidities in older adults with peripheral T cell lymphoma. Leukemia and Lymphoma 64(14):2258-2268. PMID: 37706491.

Review Articles

1. Nahmod, KA, Thakral, B, Aakash, FN, Iyer, SP, Medeiros, LJ, Quesada, AE. From the archives of MD Anderson Cancer Center. Annals of Diagnostic Pathology 62, 2023. e-Pub 2023. PMID: 36549077.
2. Prakash R, Subbiah V, Iyer SP. Evolving Landscape of Antibody Drug Conjugates in Lymphoma. Cancer J 28(6):479-487, 2022. e-Pub 2022. PMID: 36383911.
3. Khan M, Samaniego F, Hagemeister FB, Iyer SP. Emerging Therapeutic Landscape of Peripheral T-Cell Lymphomas Based on Advances in Biology: Current Status and Future Directions. Cancers (Basel) 13(22), 2021. e-Pub 2021. PMID: 34830782.
4. Torres-Cabala CA, Huen A, Iyer SP, Miranda RN. Gamma/Delta Phenotype in Primary Cutaneous T-cell Lymphomas and Lymphoid Proliferations: Challenges for Diagnosis and Classification. Surg Pathol Clin 14(2):177-194, 2021. e-Pub 2021. PMID: 34023099.
5. Chihara D, Miljkovic M, Iyer SP, Vega F. Targeted based therapy in nodal T-cell lymphomas. Leukemia 35(4):956-967, 2021. e-Pub 2021. PMID: 33664464.
6. Ma, H, Iyer, SP, Parmar, S, Gong, Y. Targeting CLL-1 for acute myeloid leukemia therapy. Journal of Hematology and Oncology 12(1), 2019. e-Pub 2019. PMID: 31014360.
7. Iyer SP, Foss FF. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. Oncologist 20(9):1084-91, 2015. e-Pub 2015. PMID: 26099743.
8. Swords, R, Mahalingam, D, Iyer, SP, Carew, J, Giles, FJ. Nilotinib. Drug Design, Development and Therapy(3):89-101, 2009. e-Pub 2009.

Other Articles

1. Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Reyes Silva, F, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K Correction to: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nature medicine 31(8):2816, 2025. PMID: 40571757.
2. Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Reyes Silva, F, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K Correction to. Nature medicine 31(8):2816, 2025. PMID: 40571757.
3. Nieto, Y, Banerjee, PP, Kaur, I, Basar, R, Li, YE, Daher, M, Rafei, H, Kerbauy, LN, Kaplan, M, Marin, D, Griffin, L, Barnett, M, Bassett Jr, R, Uprety, N, Shrestha, R, Reyes Silva, F, Islam, S, Ganesh, C, Borneo, Z, Ramdial, JL, Ramirez, A, Hosing, C, Alousi, AM, Popat, UR, Qazilbash, MH, Ahmed, S, Iyer, SP, Sainz, TP, Vega Vazquez, F, Fowlkes, NW, Alexis, K, Emig, M, Harstrick, A, Overesch, A, Shpall, E, Rezvani, K Correction to. Nature medicine 31(8):2816, 2025. PMID: 40571757.
4. Medeiros, LJ, Marques-Piubelli, ML, Sangiorgio, VF, Ruiz-Cordero, R, Vega Vazquez, F, Feldman, AL, Chapman, JR, Clemens, MW, Hunt, KK, Evans, MG, Khoo, C, Lade, S, Silberman, M, Morkowski, JJ, Pina, EM, Mills, DC, Bates, CM, Magno, WB, Sohani, AR, Sieling, BA, O'Donoghue, JM, Bacon, CM, Patani, N, Televantou, D, Turner, SD, Johnson, LL, MacNeill, F, Wotherspoon, A, Iyer, SP, Malpica Castillo, LE, Patel, KP, Xu, J, Miranda, R Corrigendum to “Epstein–Barr-virus-positive large B-cell lymphoma associated with breast implants. Modern Pathology 36(12), 2023. PMID: 37948938.
5. Alhalabi, O, Iyer, SP, Subbiah, V Testing for COVID-19 in patients with cancer. EClinicalMedicine 23, 2020. PMID: 32368727.
6. Bansal, H, Qiu, Y, Iyer, SP, Ganapathy, S, Proia, D, Penalva, LO, Uren, PJ, Suresh, U, Carew, J, Karnad, AB, Weitman, S, Tomlinson, GE, Rao, MK, Kornblau, SM, Bansal, S Erratum. Leukemia 28(12):2427, 2014.
7. Wierda, WG, Kipps, TJ, Mayer, J, Stilgenbauer, S, Williams, CD, Hellmann, A, Robak, T, Furman, RR, Hillmen, P, Trneny, M, Dyer, MJ, Iyer, SP, Piotrowska, M, Kozak, T, Chan, G, Davis, R, Losic, N, Wilms, J, Russell, CA, Österborg, A Erratum. Clinical Lymphoma, Myeloma and Leukemia 10(2):157, 2010.

Abstracts

1. Iyer SP, Hill L, Horwitz S, Jain S, Poh C, Vose JM, Brenner MK, Mamonkin M, Hein S, Giordano F, Bexon A. Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL). American Society of Hematology - ASH, 2024. e-Pub 2024.
2. Lee HJ, Ravizzini G, Aboismail E, Wixom J, Henderson J, Fayad LE, Ahmed S, Nair R, Westin JR, Iyer SP, Nze C, Zaki AA, Vega F, Wang M, Flowers CR, Malpica L. Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study. American Society of Hematology - ASH, 2024. e-Pub 2024.
3. Lionel A, Gouni S, Feng L, Gaulin C, Gonugunta AS, Saridogan T, Abreu M, Varghese J, Ow K, Santiago M, Zaki AA, Adkins S, Ayers AA, Hawkins M, Kebriaei P, Shpall EJ, Iyer SP, Jain P, Wang M, Flowers CR, Ramdial J, Nastoupil L, Westin JR, Strati P, Neelapu SS, Chatterjee D, Ahmed S. Impact of Pre-Treatment Liver-Related Factors on Clinical Outcomes after CAR T-Cell Therapy for Lymphoma. American Society of Hematology 144(Suppl 1):4506, 2024. e-Pub 2024.
4. Pawar VA, Cuesta AP, Aradhya A, Kettlun C, Iyer SP, Shukla S, Kadia TM, Vega F, Sampath D. Multiomic Single Cell Profiling Identifies Drivers of Progression in T-Cell Prolymphocytic Leukemia. American Society of Hematology - ASH, 2024. e-Pub 2024.
5. Kim K, Huen AO, Dai J, Lohray R, Dabaja BS, Gunther JR, Wu SY, Torres-Cabala CP, Nair R, Malpica L, Nieto Y, Ramdial J, Hosing C, Srour SA, Iyer SP. Outcomes after Allogeneic Stem-Cell Transplant in Patients with High-Risk Large-Cell Transformation of Mycosis Fungoides (MF-LCT). American Society of Hematology - ASH, 2024. e-Pub 2024.
6. Iyer SP, Nair R, Mehta-Shah N, Stevens DA, Tucci A, Pinto A, Zinzani PL. A Phase II Clinical Study Exploring the Safety and Efficacy of the Oral PI3Kδ Inhibitor, Linperlisib, in Relapsed Refractory T Cell Lymphoma. American Society of Hematology - ASH, 2024. e-Pub 2024.
7. Saul EE, Valcarcel B, Ayers AA, Noorani M, Chihara D, Furqan F, Ahmed S, Iyer SP, Neelapu SS, Fayad LE, Hagemeister F, Nze C, Jain P, Wang M, Strati P, Chauhan A, Vega F, Flowers CR, Westin JR. Retreatment with R-CHOP-like Therapy Is Active with Durable Responses in Patients with Late Relapse of Diffuse Large B-Cell Lymphoma. American Society of Hematology - ASH, 2024. e-Pub 2024.
8. Zain J, Iyer SP, Marchi E, Gandhi M, Kim YH, Khodadoust MS, Brammer JE, Poh C, Porcu P, Dilley K, Will M, Kantor A, Leonowens C, Tomasevic N, Prince H, Horwitz S. Results from the First Phase 1 Clinical Study of DR-01, a Non-Fucosylated Anti-CD94 Targeting Antibody in Patients with Relapsed/Refractory Cytotoxic Lymphomas: Dose Escalation and Optimization. American Society of Hematology - ASH, 2024. e-Pub 2024.
9. Lohray R, Feng L, Huen AO, Ogundipe I, Malpica L, Dabaja BS, Dai J, Gunther JR, Hosing C, Miranda RN, Medeiros L, Srour SA, Ramdial J, Vega F, Noorani M, Ayers AA, Fang PQ, Fayad LE, Pinnix CC, Duvic M, Xu J, Flowers CR, Wu SY, Kim K, Torres-Cabala CP, Iyer SP, Nair R. Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases. American Society of Hematology - ASH 144(Suppl 1):1679, 2024. e-Pub 2024.
10. Bermack C, Pan K, Chiu Y, Malpica L, Iyer SP, Flowers CR, Yee C. Developing Novel Cellular Therapies for Cutaneous T Cell Lymphoma (CTCL): Combining Immunopeptidomics and Endogenous T Cell (ETC) Therapy Platforms to Identify and Target Shared CTCL-Associated Antigens. American Society of Hematology - ASH, 2024. e-Pub 2024.
11. Lee HJ, Ravizzini G, Aboismail E, Wixom J, Henderson J, Fayad LE, Ahmed S, Nair R, Westin JR, Iyer SP, Nze C, Zaki AA, Vega F, Wang M, Flowers CR, Malpica L. Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study. American Society of Hematology, 2024. e-Pub 2024.
12. Kim K, Chihara D, Fayad LE, Neelapu SS, Ahmed S, Hagemeister F, Nze C, Iyer SP, Jain P, Wang M, Strati P, Furqan F, Chauhan A, Green MR, Flowers CR, Westin JR. Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma. American Society of Hematology, 2024. e-Pub 2024.
13. Maiti A, Daver N, Johnson WT, Goyal G, Broome CM, Gohil S, Laar JV, Jimenez JL, McCall D, Lane H, Kim B, Panicker S, Patou G, Moore S, Mangal B, Covert K, Parry GC, Dong K, Allen C, Iyer SP. ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis. American Society of Hematology - ASH 144(Suppl 1):805, 2024. e-Pub 2024.
14. Elias A, Prakash R, Nair R, Malpica L, Lee HJ, Maples E, Carlson S, Fayad LE, Patel KK, Ahmed S, Iyer SP. Risk Analysis of Cytokine Release Syndrome, Immune Effector Cell- Associated Neurotoxicity Syndrome, and Immune Effector Cell- Associated Hemophagocytic Lymphohistiocytosis-like Syndrome in BiTE Therapy Vs CAR-T Therapy Using Real World Data. American Society of Hematology, 2024. e-Pub 2024.
15. Romero C, Roa M, Idrobo H, Castro D, Beltran BE, Enriquez DJ, Vasquez JF, Roche C, Artiles D, Valvert F, Villela Martinez LM, Pereira J, Oliver AC, Tavarez JV, B Brasil SA, Cecyn KZ, Castro NS, R Baptista RL, Medina SS, Maciel Borducchi DM, Bellesso M, De Farias DLC, Gonzaga Y, Korin L, Pereyra P, Peña C, Torres Viera MA, Meza K, Glasenapp SV, Quiroz A, Samanez-Figari C, Rios Jimenez RO, Paredes S, Fischer T, Trabolsi A, Schatz JH, Iyer SP, Nair R, Saul EE, Bermack C, Castillo JJ, Souza CD, Miranda E, Valcarcel B, Chiattone C, Malpica Castillo LE. Refining Prognostication in Peripheral T Cell Lymphoma (PTCL): A Risk-Adapted Prognostic Model for Patients with Limited-Stage PTCL. American Society of Hematology 144(Suppl 1):983, 2024. e-Pub 2024.
16. Prakash R, Long J, Mescher B, Jr PE, Knafl M, Jin J, Kell T, Garg N, Zaki AA, Chihara D, Malpica L, Nair R, Iyer SP. Utility of PET/CT Imaging in Predicting Outcomes of Patients with Lymphoid Malignancy-Associated Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis from a Single Tertiary Center. American Society of Hematology, 2024. e-Pub 2024.
17. Garcia-Robledo JE, Quintero H, Castro D, Beltran BE, Enriquez DJ, Vasquez JF, Roche C, Artiles D, Valvert F, Villela Martinez LM, Pereira J, Oliver AC, Tavarez JV, B Brasil SA, Cecyn KZ, Castro NS, R Baptista RL, Medina SS, Maciel Borducchi DM, Bellesso M, De Farias DLC, Gonzaga Y, Korin L, Pereyra P, Peña C, Roa M, Torres Viera MA, Meza K, Glasenapp SV, Quiroz A, Samanez-Figari C, Rios Jimenez RO, Paredes S, Fischer T, Trabolsi A, Schatz JH, Iyer SP, Nair R, Saul EE, Bermack C, Castillo JJ, Souza CD, Miranda E, Valcarcel B, Chiattone C, Malpica Castillo LE. Clinical Features, Therapy Patterns and Survival Outcomes of Limited-Stage Peripheral T-Cell Lymphomas: A Cross-Continental Study. American Society of Hematology, 2024. e-Pub 2024.
18. Lionel A, Kui N, Sun R, Aboismail E, Tewari SO, Zaki AA, Gouni S, Jain P, Chihara D, Iyer SP, Wang M, Nair R, Malpica Castillo LE, Lee HJ, Nze C, Fayad LE, Hagemeister F, Rodriguez MA, Ayers AA, Gutierrez C, Rondon G, Khawaja F, Kebriaei P, Shpall EJ, Flowers CR, Westin JR, Strati P, WANG W, Wang SA, Ahmed S, Neelapu SS. Peripheral Blood CAR T-Cell Level Using a Clia-Validated Assay Is Prognostic for Treatment Response and Icans in Large B-Cell Lymphoma. American Society of Hematology, 2024. e-Pub 2024.
19. Nair R, Duenas DE, Liu J, Prakash R, Zhou C, Koksoy AA, Xu J, McAllen SA, Malpica L, Luthra R, Vega F, Miranda R, Zhang J, Medeiros LJ, Haymaker CL, Flowers CR, Neelapu SS, Iyer SP. An Integrated Spatial, Codex, and Genomic Analysis Predicts Responsiveness and Survival in the Phase II Combination of Pembrolizumab and Romidepsin in PTCL. American Society of Hematology (ASH), 2024. e-Pub 2024.
20. Gonugunta AS, Prakash R, Nair R, Zaki AA, Ahmed S, Nze C, Chihara D, Hagemeister F, Lee HJ, Westin JR, Patel KK, Fayad LE, Malpica L, Rodriguez MA, Wang M, Jain P, Strati P, Neelapu SS, Flowers CR, Iyer SP. T-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis Has Worse Survival When Compared to T-Cell Lymphoma: A Retrospective Analysis from a Single Tertiary Center. American Society of Hematology - ASH, 2024. e-Pub 2024.
21. Jain P, Chi Young OK, Nastoupil LJ, Westin J, Hill HA, Nair R, Iyer SP, Fetooh A, Lee HJ, Ahmed S, Kanagal-Shamanna R, Jelloul FZ, Malpica Castillo LE, Liu Y, Li Y, Vargas J, Feng L, Badillo M, Thirumurthi S, Xu G, Deswal A, Iliescu C, Nguyen VQ, Tang G, Patel KP, Vega F, Medeiros L, Wang ML, Flowers CR. Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma - a Phase II Clinical Trial. American Society of Hematology (ASH), 2024. e-Pub 2024.
22. Pawar VA, Aradhya A, Galvan D, Borthakur G, Iyer SP, Kirschbaum M, Blake D, Kadia TM, Sampath D, Vega F. Preclinical Evaluation of T-Cell Prolymphocytic Leukemia Demonstrates Heterogeneous BCL2-Family Dependency That May be Effectively Targeted with Small Molecule Inhibitors. American Society of Hematology (ASH), 2024. e-Pub 2024.
23. Khouri IF, Gruschkus SK, Ledesma C, Anderlini P, Bashir Q, Daher M, Iyer SP, Marin D, Mehta R, Olson AL, Popat UR, Samaniego F, Qazilbash MH, Im JS, Rondon G, Champlin RE, Gulbis A, Young KH. Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. American Society of Hematology (ASH), 2024. e-Pub 2024.
24. Patel K, Ramchandren R, Maris M, Lesokhin AM, von Keudell GR, Cheson BD, Zonder J, Seymour EK, Catalano T, Y Lin GH, Uger B, Petrova PS, Roberge K, Shou Y, Iyer SP. Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. American Society of Hematology (ASH), 2024. e-Pub 2024.
25. Ebinama U, Prakash R, Strati P, Ahmed S, Adkins S, Srour SA, Wang ML, Jain P, Shpall EJ, Lionel A, Lui M, Neelapu SS, Patel KK, Iyer SP. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS): A Review of Pharmacovigilance. American Society of Hematology (ASH), 2023. e-Pub 2023.
26. Iyer SP, Haverkos BM, Zain J, Ramchandren R, Lechowicz MJ, Devata S, Korman N, Pinter-Brown LC, Routhu KV, Barde P, Nair AM, Huen A. Final Results of Phase 1/1b Study of Tenalisib, Dual PI3K δ/γ Inhibitor in Patients with Relapsed/Refractory T-Cell Lymphoma. American Society of Hematology (ASH), 2023. e-Pub 2023.
27. Marques-Piubelli ML, Soto LS, Iyer SP, Sagert J, Pham MT, Tipton K, Lu W, Khan KB, Hamana Zorrilla LG, Chapman JR, Thakral B, Xu J, Miranda RN, Jennings K, Vega F. CD70 Expression in Mature T-Cell Lymphomas. American Society of Hematology (ASH), 2023. e-Pub 2023.
28. Wang M, Jain P, Lee HJ, Ok CY, Hill H, Navsaria L, Kanagal-Shamanna R, Malpica-Castillo L, Nair R, Iyer SP, Samaniego F, Chen W, Oriabure O, Feng L, Thirumurthi S, Santos D, Tang G, Vega F, Li S, Avellaneda M, Badillo M, Flowers CR. Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-2 Clinical Trial. American Society of Hematology (ASH), 2023. e-Pub 2023.
29. Elias A, Marques-Piubelli ML, Nair R, Prakash R, Ahmed S, Malpica L, Lee HJ, Xu J, Flowers CR, Neelapu SS, Vega F, Miranda R, Iyer SP. Prognostic Significance of CD30 Expression and Response to Brentuximab Vedotin in Patients with Angioimmunoblastic T Cell Lymphoma. American Society of Hematology (ASH), 2023. e-Pub 2023.
30. Westin J, Nair R, Fayad L, Iyer SP, Malpica L, Neelapu SS, Samaniego F, Steiner RE, Strati P, Mathew S, Griffith D, Nastoupil LJ, Montinez W, Rodriguez MA, Hagemeister F, Feng L, Vega F, Flowers CR, Ahmed S. Nivolumab and Ibrutinib for Treatment of Patients with Refractory or Relapsed Central Nervous System Lymphoma. American Society of Hematology (ASH), 2023. e-Pub 2023.
31. Maiti A, Daver N, Iyer SP, McCall D, Gohil SH, Jimenez JL, Lane H, Kim B, Dao K, Patou G, Panicker S, Covert K, Parry GC, Allen CE. A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis. American Society of Hematology (ASH), 2023. e-Pub 2023.
32. Iyer SP, Ayyappan SR, Greenwell IB, Kim WS, Lee ST, Kim JS, Lee W, Jeon Y, Johnson W, Dave UP, Yoon S, Kang K, Carrette F, Viotti J, Leyco AJ, Muller M, Horwitz SM. Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data. American Society of Hematology (ASH), 2023. e-Pub 2023.
33. Gaulin C, Jain P, Nair R, Iyer SP, Lee HJ, Fayad L, Feng L, Liu Y, Hill HA, Li Y, Ok CY, Kanagal-Shamanna R, Oriabure O, Chen W, Siddiqui A, Xu G, Deswal A, Iliescu C, Badillo M, Li S, Ky M, Avellaneda M, Tang G, Vega F, Flowers CR, Wang ML. Phase II Trial of Ibrutinib in Previously Untreated High-Risk Smoldering Mantle Cell Lymphoma. American Society of Hematology (ASH), 2023. e-Pub 2023.
34. Iyer SP, Mehta-Shah N, Advani RH, Bartlett NL, Christensen JH, Morschhauser F, Domenech EVA, Pagani C, Kim WS, Alpdogan O, Suh C, Feldman T, Tilly H, Zinzani PL, Rambaldi A, Belada D, Mayer J, Choi I, Cheong J, Jain S, Keenan F, Fanale MA, Savage KJ, Horwitz SM. PET4 Response as an Independent Predictor of Long-Term Outcomes in ECHELON2 (A+CHP Vs. CHOP) in CD30+PTCL. American Society of Hematology, 2023. e-Pub 2023.
35. Westin J, Steiner RE, Chihara D, Ahmed S, Jain P, Malpica L, Iyer SP, Fayad L, Nair R, Nastoupil LJ, Neelapu SS, Henderson J, Rodriguez MA, Hagemeister F, Vega F, Pulsifer B, Tom J, Durmic I, Masand G, Feng L, Green MR, Flowers CR, Strati P. Smart Stop: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma. American Society of Hematology (ASH), 2023. e-Pub 2023.
36. Zoref-Lorenz A, Iyer SP, Murakami J, Hofstetter L, Prakash R, Weinstein S, Yacobovich J, Izraeli S, Nikiforow S, Gurion R, Cohen I, Raanani P, Nagler A, Berliner N, Ellis MH, Itchaki G, Jordan MB, Pottinger D, Razanamahery J, Wang Z, Goyal G. Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society. American Society of Hematology (ASH), 2023. e-Pub 2023.
37. Zhou C, Xu J, Prakash R, Torres-Cabala CP, Chen C, Madduri K, Rao A, Agasthya G, Vega F, O'Malley D, Medeiros L, Kumara S, Iyer SP. Developing Deep Learning Pipeline of Whole-Slide Images for Enhanced Diffuse Large B Cell Lymphoma (DLBCL) Subtyping and Outcome Prediction: Leveraging Self-Attention Transformer for Training and Inference. American Society of Hematology (ASH), 2023. e-Pub 2023.
38. Lionel A, Long J, Prakash R, Edelkamp P, Jr, Knafl M, Ahmed S, Strati P, Nair R, Chien KS, Chihara D, Westin J, Khawaja F, Nastoupil LJ, Manzano J, Mulanovich V, Team D, Daver N, Futreal A, Woodman SE, Flowers CR, Neelapu SS, Iyer SP. Differing Inflammatory Profiles and Survival Outcomes of Cytokine Storm Arising from CAR T-Cell Therapy, COVID and Malignancy-Associated HLH in Patients with Hematological Malignancies. American Society of Hematology (ASH), 2023. e-Pub 2023.
39. Jain P, Lee HJ, Westin J, Nastoupil LJ, Fayad L, Nair R, Iyer SP, Kanagal-Shamanna R, Fetooh A, Hill HA, Ok CY, Chen W, Oriabure O, Feng L, Tang G, Vega F, Badillo M, Flowers CR, Wang ML. Six Years Follow up of Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hyper CVAD/MTX in Patients (age ≤ 65 years) with Previously Untreated Mantle Cell Lymphoma - Phase-II Window-1 Clinical Trial. American Society of Hematology (ASH), 2023. e-Pub 2023.
40. Lee HC, Li J, Lin H, Murga AD, Rodriguez GM, Mohamed ME, Henderson J, Rodriguez S, Becnel MR, Weber DM, Iyer SP, Kaufman GP, Thomas SK, Manasanch EE, Patel KK, Noga SJ, Green MR, Orlowski RZ, Haymaker CL. Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in -Class Transition ( i CT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma. American Society of Hematology (ASH), 2023. e-Pub 2023.
41. Nair R, Ogundipe I, Gunther J, Medeiros L, Jain P, Nastoupil LJ, Pinnix CC, Malpica L, Ahmed S, Miranda R, Fayad L, Steiner RE, Hagemeister F, Lee HJ, Rodriguez MA, Strati P, Chihara D, Wang M, Nieto Y, Ramdial J, Zaki AA, Nze C, Green MR, Dabaja BS, Xu J, Thakral B, Neelapu SS, Vega F, Flowers CR, Fang P, Westin J, Feng L, Iyer SP. Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience. American Society of Hematology (ASH), 2023. e-Pub 2023.
42. Bhansali RS, Ellin F, Cao M, Relander T, Li W, Long Q, Ganesan N, Stuver R, Horwitz SM, Wudhikarn K, Hwang SR, Bennani N, Chavez JC, Sokol L, Saeed H, Duan F, Porcu P, Pullarkat P, Mehta-Shah N, Zain J, Ruiz M, Brammer JE, Prakash R, Iyer SP, Olszewski AJ, Major A, Smith SM, Riedell PA, Goldin C, Haverkos BM, Hu B, Allen PB, Toama W, Janakiram M, Brooks T, Jagadeesh D, Hariharan N, Goodman AM, Ghione P, Fayyaz F, Rhodes JM, Chong EA, Gerson JN, Landsburg DJ, Nasta SD, Schuster SJ, Svoboda J, Jerkeman M, Barta SK. CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas. American Society of Hematology (ASH), 2023. e-Pub 2023.
43. Santiesteban DY, Duncan AD, Mirza NQ, Jacques V, DeWitt S, Iyer SP. SP-3164, a Novel Cereblon-Binding Protein Degrader, Shows Activity in Preclinical Lymphoma Models. American Society of Hematology (ASH), 2023. e-Pub 2023.
44. Pinnix CC, Dabaja BS, Gunther JR, Fang P, Wu S, Ahmed S, Steiner RE, Nair R, Strati P, Westin J, Fayad L, Iyer SP, Rodriguez MA, Lee HJ, Samaniego F, Chihara D, Jain P, Feng L, Flowers CR, Neelapu SS, Nastoupil LJ. Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma. American Society of Hematology (ASH), 2023. e-Pub 2023.
45. Bhansali RS, Ganesan N, Stuver RN, Horwitz SM, Wudhikarn K, Hwang SR, Bennani N, Chavez JC, Sokol L, Saeed H, Pullarkat P, Mehta-Shah N, Prakash R, Iyer SP, Olszewski AJ, Goldin C, Haverkos BM, Allen P, Chong EA, Gerson JN, Landsburg DJ, Nasta S, Schuster SJ, Svoboda J, Barta SK. A Multi-Institutional Retrospective Analysis of T-Cell Lymphomas with Central Nervous System Relapse. American Society of Hematology (ASH), 2023. e-Pub 2023.
46. Hadidi SA, Nair R, Steiner RE, Ahmed S, Strati P, Parmar S, Iyer SP, Gunther JR, Pinnix CC, Dabaja BS, Nieto Y, Samaniego F, Cuglievan B, Jain P, Fang P, Miranda RN, Medeiros J, Feng L, Chuang H, Wang M, Lee HJ. Real Life Treatment Alterations of Frontline Therapies in Classic Hodgkin's Lymphoma. American Society of Hematology (ASH), 2023. e-Pub 2023.
47. Hadidi SA, Nair R, Steiner RE, Ahmed S, Strati P, Parmar S, Iyer SP, Gunther JR, Pinnix CC, Dabaja BS, Nieto Y, Samaniego F, Cuglievan B, Jain P, Fang P, Miranda RN, Medeiros L, Feng L, Chuang H, Wang M, Lee HJ. Association of Smoking with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma. American Society of Hematology (ASH), 2023. e-Pub 2023.
48. Iyer SP, Huen A, Haverkos B, Ai WZ, Okada C, Kuzel TM, Lechowicz MJ, Alderuccio JP, Mohrbacher A, Stevens DA, Wilcox RA, Feldman TA, Sundaram S, Jagadeesh D, Reddy N, Routhu KV, Barde P, Nair AM. A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma. American Society of Hematology (ASH), 2023. e-Pub 2023.
49. Srour SA, Xu J, Al-Juhaishi T, Steiner RE, Ensor J, Ahmed S, Parmar S, Strati P, Nastoupil LJ, Nieto Y, Hosing C, Lee HJ, Westin J, Fowler NH, Fayad L, Dabaja BS, Pinnix CC, Gunther JR, Fang P, Samaniego F, Jain P, Champlin RE, Khouri IF, Wang M, Miranda RN, Vega F, Neelapu SS, Flowers C, Iyer SP. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. American Society of Hematology (ASH), 2023. e-Pub 2023.
50. Horwitz SM, O'Connor OA, Pro B, Illidge T, Iyer SP, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman TA, Menne T, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh S, Shustov AR, Hüttmann A, Savage KJ, Yuen S, Zinzani PL, Miao H, Bunn V, Fenton K, Fanale MA, Puhlmann M, Truemper L. The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. American Society of Hematology (ASH), 2023. e-Pub 2023.
51. Strati P, Mistry H, Pulsifer B, Fayad L, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Dabaja BS, Noorani M, Claussen CM, Shpall EJ, Kebriaei P, Flowers CR, Westin JR, Neelapu SS. Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. American Society of Hematology (ASH), 2023. e-Pub 2023.
52. Khouri IF, Milton DR, Ledesma C, Jabbour E, Bashir Q, Im JS, Fayad L, Lee HJ, Nair R, Nastoupil LJ, Samaniego F, Iyer SP, Flowers C, Champlin RE, Sharma P, Gulbis A. Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma. American Society of Hematology (ASH), 2023. e-Pub 2023.
53. Hadidi SA, Nair R, Steiner RE, Ahmed S, Strati P, Parmar S, Iyer SP, Gunther JR, Pinnix CC, Dabaja BS, Nieto Y, Samaniego F, Cuglievan B, Jain P, Fang P, Miranda RN, Medeiros J, Feng L, Chuang H, Wang M, Lee HJ. Association of Epstein-Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma. American Society of Hematology (ASH), 2023. e-Pub 2023.
54. Iyer SP, Xu J, Becnel MR, Nair R, Steiner R, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil LJ, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, Im JS, Jain P, Fayad L, Wang M, Miranda RN, Vega F, Flowers C, Neelapu SS. A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). American Society of Hematology (ASH), 2023. e-Pub 2023.
55. Thomas SK, Shah JJ, Morin A, Morphey AN, Lee HC, Manasanch EE, Patel KK, Kaufman GP, Iyer SP, Feng L, Amini B, Qazilbash MH, Bashir Q, Saini N, Srour SA, Johnson RJ, Crumpton BN, Stafford MD, Weber DM, Orlowski RZ. Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). American Society of Hematology (ASH), 2023. e-Pub 2023.
56. Zoref-Lorenz A, Murakami J, Hofstetter L, Abadi U, Iyer SP, Mohamed SF, Natour AEH, Weinstein S, Yacobovich J, Izrael S, Nikiforow S, Gurion R, Cohen I, Pasvolsky O, Raanani P, Nagler A, Berliner N, Daver N, Ellis MH, Goyal G, Jordan MB. The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation. Blood (ASH) 140(Suppl 1):8326-8328, 2022. e-Pub 2022.
57. Strati P, Xubin Li X, Deng Q, Feng L, Sun R, Jallouk A, Adkins S, Cain T, Johncy S, Steiner RE, Ahmed S, Chihara D, Fayad L, Iyer SP, Horowitz SB, Nehlsen R, Nastoupil LJ, Nair R, Hassan A, Daoud T, Hawkins M, Samaniego F, Rodriguez MA, Shpall EJ, Kebriaei P, Flowers CR, Hong D, Westin J, Neelapu SS, Green MR. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma. Blood (ASH) 140(Suppl 1):7493-95, 2022. e-Pub 2022.
58. Nair R, Ayers A, Nastoupil LJ, Gunther JR, Fayad L, Fowler NH, Miranda RN, Hagemeister FB, Lee HJ, Rodriguez MAR, Steiner R, Strati P, Nieto Y, Ramdial JL, Chihara D, Wang ML, Malpica Castillo LE, Saini N, Jain P, Pinnix CC, Dabaja BS, Green MR, Flowers CR, Medeiros LJ, Marques-Piubelli ML, Vega V, Noorani M, Ahmed S, Westin J, Neelapu SS, Feng L, Iyer SP. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL. Blood (ASH) 140(Suppl 1):3800-3802, 2022. e-Pub 2022.
59. Li X, Deng Q, Henderson J, Watson G, Deaton L, Cain T, Fayad L, Iyer SP, Hagemeister FB, Nastoupil LJ, Fowler NH, Westin J, Steiner R, Nair R, Ahmed S, Alatrash G, Neelapu SS, Strati P, Green MR. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy. Blood (ASH) 140(Suppl 1):4502-4503, 2022. e-Pub 2022.
60. Elias A, Prakash R, Nastoupil LJ, Fowler NH, Ahmed S, Nair R, Malpica Castillo LE, Dabaja BS, Xu J, Medeiros J, Stewart J, Wang W, Pinnix CC, Hunt K, Clemens MW, Miranda RN, Iyer SP. Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin. Blood (ASH) 140(Suppl 1):3721-3723, 2022. e-Pub 2022.
61. Elias A, Prakash R, Nastoupil LJ, Fowler NH, Ahmed S, Nair R, Malpica Castillo LE, Dabaja BS, Xu J, Medeiros J, Stewart J, Wang W, Pinnix CC, Hunt K, Clemens MW, Miranda RN, Iyer SP. Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin. Blood (ASH) 140(Suppl 1):3721-3723, 2022. e-Pub 2022.
62. Aradhya A, Agarwal N, Iyer SP, Huang F, Vega F. Pharmacological Inhibitory Effect of Imetelstat, a Novel Human Telomerase Inhibitor in Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma. Blood (ASH) 140(Suppl 1):11932-11933, 2022. e-Pub 2022.
63. Ebinama U, Ai S, Ahmed S, Lee HJ, Liu M, Iyer SP. Risk of Pneumonitis with Immune Checkpoint Inhibitors in Hodgkin's Lymphoma and Other Hematologic Malignancies: A Retrospective Review from Pharmacovigilance. Blood (ASH) 140(Suppl 1):5183-5184, 2022. e-Pub 2022.
64. Nze C, Andersen CR, Ayers A, Westin J, Wang ML, Iyer SP, Ahmed S, Pinnix CC, Vega F, McNeil L, Nguyen L, Nastoupil LJ, Flowers CR. Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution. Blood (ASH) 140(Suopl 1):7943-7945, 2022. e-Pub 2022.
65. Fa K, Prakash R, Sassine J, Handley G, VanWieren T, Angelidakis G, Iyer SP, Ramdial JL, Ahmed S, Nieto Y, Spallone A, Ariza-Heredia EJ, Chemaly R. Cytomegalovirus (CMV) Reactivation within in the First Year after Chimeric Antigen Receptor (CAR) T Cell Therapy: Experience from the First Two Years at a Major Cancer Center. Blood (ASH) 140(Suppl 1):7533-7535, 2022. e-Pub 2022.
66. Agbedia OO, Prakash R, Xu J, Becnel MR, Nair R, Steiner RE, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil LJ, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, Im JS, Fayad L, Jain P, Wang ML, Miranda RN, Vega F, Medeiros J, Oki Y, Flowers CR, Neelapu SS, Iyer SP. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis. Blood (ASH) 140(Suppl 1):2313-2315, 2022. e-Pub 2022.
67. Nieto Y, Valdez BC, Thall PF, Ramdial JL, Srour SA, Hosing C, Saini N, Alousi AM, Qazilbash MH, Popat UR, Gulbis A, Shigle TL, Bassett R, Guillermo-Pacheco M, Ledesma C, Strati P, Ahmed S, Steiner R, Westin J, Nair R, Iyer SP, Champlin RE, Shpall EJ, Andersson BS. High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas. Blood (ASH) 140(Suppl 1):1883-1184, 2022. e-Pub 2022.
68. Allen PB, Goyal S, Iyer SP, Talluru S, Huen A, Greenwell IB, Scribner J, Speegle S, Niyogusaba T, Rangarajan S, Mehta A, O'Leary CB, Beaven AW, Switchenko JM, Ayers A, Bhatti S, Krishnasamy S, Porcu P, Sethi T, Foss FM, Lechowicz MJ, Rozati S. Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers. Blood (ASH) 140(Suppl 1):9431-9433, 2022. e-Pub 2022.
69. Prakash R, Long J, Edelkamp Jr P, Knafl M, Ahmed S, Khawaja F, Nastoupil LJ, J-G, Mulanovich V, Prabhakaran S, Futreal A, Woodman SE, Iyer SP. Prediction of Mortality Following Cytokine Storm in Patients with Hematological Malignancies and COVID-19 Infections. Blood (ASH) 140(Suppl 1), 2022. e-Pub 2022.
70. Nguyen CN, Prakash R, Duvic M, Heberton M, Dai J, Nair R, Malpica Castillo LE, Cabala CT, Feng L, Iyer SP, Huen A. Prognostic Significance of Cutaneous Angioimmunoblastic T-Cell Lymphoma: Correlation of Clinical, Histologic and Immunophenotypic Features with Response. Blood (ASH) 140(Suppl 1):9406–9407, 2022. e-Pub 2022.
71. Jallouk A, Feng L, Noorani M, Das K, Steiner RE, Nastoupil LJ, Hawkins M, Nair R, Westin W, Fayad L, Chihara D, Malpica Castillo LE, Iyer SP, Ahmed S, Shpall EJ, Kebriaei P, Neelapu SS, Strati P. Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy. Blood (ASH) 140(Suppl 1):10424–10426, 2022. e-Pub 2022.
72. Nair R, Prakash R, Dang A, Gunther JR, Huen A, Xu J, Malpica Castillo LE, Torres Cabala C, Heberton M, Fang P, Ahmed S, Miranda RN, Fayad L, Steiner R, Lee HJ, Chihara D, Jain P, Srour SA, Ramdial JL, Nieto Y, Nastoupil LJ, Pinnix CC, Neelapu SS, Flowers CR, Medeiros LJ, Hosing H, Wang ML, Dabaja BS, Vega F, Feng L, Iyer SP. Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma. Blood (ASH) 140(Suppl 1):12005–12007, 2022. e-Pub 2022.
73. Lee HC, Kaufman GP, Feng L, Murga A, Johnson RJ, Weber D, Thomas SK, Bashir Q, Qazilbash MH, Iyer SP, Patel K, Becnel MR, Manasanch EE, Orlowski RZ. Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis. Blood (ASH) 140(Suppl 1):4428–4430, 2022. e-Pub 2022.
74. Jain P, Ok CY, Fetooh A, Kanagal-Shamanna R, Jelloul FZ, Hill H, Floyd K, Loghavi S, Zuo Z, Yin CC, Routbort M, Tang G, Ahmed S, Malpica Castillo LE, Siddiqui A, Chen W, Oriabure O, Badillo M, Steiner RE, Iyer SP, Lee HJ, Luthra R, Vega F, Flowers CR, Medeiros J, Wang ML, Patel KP, Fowler NH, Nair R. Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma. Blood (ASH) 140(Suppl 1):3598–3600, 2022. e-Pub 2022.
75. Nieto Y, Banerjee PP, Kaur I, Griffin L, Ganesh C, Kerbauy L, Basar R, Kaplan M, Islam S, Esqueda D, Bassett R, Timmons M, Ramdial JL, Srour SA, Saini N, Hosing C, Ahmed S, Iyer SP, Alexis K, Emig M, Harstrick A, Shpall EJ, Rezvani K. Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma. Blood (ASH) 140(Suppl 1):415-16, 2022. e-Pub 2022.
76. Elias A, Prakash R, Nastoupil LJ, Fowler NH, Ahmed S, Nair R, Malpica Castillo LE, Dabaja BS, Xu J, Medeiros J, Stewart J, Wang W, Pinnix CC, Hunt K, Clemens MW, Miranda RN, Iyer SP. Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin. Blood (ASH) 140(Suppl 1):3721-3723, 2022. e-Pub 2022.
77. Li X, Deng Q, Henderson J, Watson G, Deaton L, Cain T, Fayad L, Iyer SP, Hagemeister FB, Nastoupil LJ, Fowler NH, Westin J, Steiner R, Nair R, Ahmed S, Alatrash G, Neelapu SS, Strati P, Green MR. Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy. Blood (ASH) 140(Suppl 1):4502-4503, 2022. e-Pub 2022.
78. Nair R, Ayers A, Nastoupil LJ, Gunther JR, Fayad L, Fowler NH, Miranda RN, Hagemeister FB, Lee HJ, Rodriguez MAR, Steiner R, Strati P, Nieto Y, Ramdial JL, Chihara D, Wang ML, Malpica Castillo LE, Saini N, Jain P, Pinnix CC, Dabaja BS, Green MR, Flowers CR, Medeiros LJ, Marques-Piubelli ML, Vega V, Noorani M, Ahmed S, Westin J, Neelapu SS, Feng L, Iyer SP. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL. Blood (ASH) 140(Suppl 1):3800-3802, 2022. e-Pub 2022.
79. Strati P, Xubin Li X, Deng Q, Feng L, Sun R, Jallouk A, Adkins S, Cain T, Johncy S, Steiner RE, Ahmed S, Chihara D, Fayad L, Iyer SP, Horowitz SB, Nehlsen R, Nastoupil LJ, Nair R, Hassan A, Daoud T, Hawkins M, Samaniego F, Rodriguez MA, Shpall EJ, Kebriaei P, Flowers CR, Hong D, Westin J, Neelapu SS, Green MR. Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma. Blood (ASH) 140(Suppl 1):7493-95, 2022. e-Pub 2022.
80. Nieto Y, Banerjee PP, Kaur I, Griffin L, Ganesh C, Kerbauy L, Basar R, Kaplan M, Islam S, Esqueda D, Bassett R, Timmons M, Ramdial JL, Srour SA, Saini N, Hosing C, Ahmed S, Iyer SP, Alexis K, Emig M, Harstrick A, Shpall EJ, Rezvani K. Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma. Blood (ASH) 140(Suppl 1):415-16, 2022. e-Pub 2022.
81. Jain P, Ok CY, Fetooh A, Kanagal-Shamanna R, Jelloul FZ, Hill H, Floyd K, Loghavi S, Zuo Z, Yin CC, Routbort M, Tang G, Ahmed S, Malpica Castillo LE, Siddiqui A, Chen W, Oriabure O, Badillo M, Steiner RE, Iyer SP, Lee HJ, Luthra R, Vega F, Flowers CR, Medeiros J, Wang ML, Patel KP, Fowler NH, Nair R. Mutation Spectrum, Characteristics and Impact of Mutation Profiling on Prognosis, Outcome and Treatment Responses in Patients (pts) with Mantle Cell Lymphoma. Blood (ASH) 140(Suppl 1):3598–3600, 2022. e-Pub 2022.
82. Lee HC, Kaufman GP, Feng L, Murga A, Johnson RJ, Weber D, Thomas SK, Bashir Q, Qazilbash MH, Iyer SP, Patel K, Becnel MR, Manasanch EE, Orlowski RZ. Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis. Blood (ASH) 140(Suppl 1):4428–4430, 2022. e-Pub 2022.
83. Nair R, Prakash R, Dang A, Gunther JR, Huen A, Xu J, Malpica Castillo LE, Torres Cabala C, Heberton M, Fang P, Ahmed S, Miranda RN, Fayad L, Steiner R, Lee HJ, Chihara D, Jain P, Srour SA, Ramdial JL, Nieto Y, Nastoupil LJ, Pinnix CC, Neelapu SS, Flowers CR, Medeiros LJ, Hosing H, Wang ML, Dabaja BS, Vega F, Feng L, Iyer SP. Cutaneous/ Subcutaneous Involvement - an Immune privileged Site Associated with Poor Outcomes in Systemic Peripheral T/ NK Cell Lymphoma. Blood (ASH) 140(Suppl 1):12005–12007, 2022. e-Pub 2022.
84. Jallouk A, Feng L, Noorani M, Das K, Steiner RE, Nastoupil LJ, Hawkins M, Nair R, Westin W, Fayad L, Chihara D, Malpica Castillo LE, Iyer SP, Ahmed S, Shpall EJ, Kebriaei P, Neelapu SS, Strati P. Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy. Blood (ASH) 140(Suppl 1):10424–10426, 2022. e-Pub 2022.
85. Elias A, Prakash R, Nastoupil LJ, Fowler NH, Ahmed S, Nair R, Malpica Castillo LE, Dabaja BS, Xu J, Medeiros J, Stewart J, Wang W, Pinnix CC, Hunt K, Clemens MW, Miranda RN, Iyer SP. Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin. Blood (ASH) 140(Suppl 1):3721-3723, 2022. e-Pub 2022.
86. Nguyen CN, Prakash R, Duvic M, Heberton M, Dai J, Nair R, Malpica Castillo LE, Cabala CT, Feng L, Iyer SP, Huen A. Prognostic Significance of Cutaneous Angioimmunoblastic T-Cell Lymphoma: Correlation of Clinical, Histologic and Immunophenotypic Features with Response. Blood (ASH) 140(Suppl 1):9406–9407, 2022. e-Pub 2022.
87. Prakash R, Long J, Edelkamp Jr P, Knafl M, Ahmed S, Khawaja F, Nastoupil LJ, J-G, Mulanovich V, Prabhakaran S, Futreal A, Woodman SE, Iyer SP. Prediction of Mortality Following Cytokine Storm in Patients with Hematological Malignancies and COVID-19 Infections. Blood (ASH) 140(Suppl 1), 2022. e-Pub 2022.
88. Allen PB, Goyal S, Iyer SP, Talluru S, Huen A, Greenwell IB, Scribner J, Speegle S, Niyogusaba T, Rangarajan S, Mehta A, O'Leary CB, Beaven AW, Switchenko JM, Ayers A, Bhatti S, Krishnasamy S, Porcu P, Sethi T, Foss FM, Lechowicz MJ, Rozati S. Differences in Progression and Survival Among Black Patients with Mycosis Fungoides and Sézary Syndrome: A Multicenter Retrospective Analysis at Large Urban Medical Centers. Blood (ASH) 140(Suppl 1):9431-9433, 2022. e-Pub 2022.
89. Nieto Y, Valdez BC, Thall PF, Ramdial JL, Srour SA, Hosing C, Saini N, Alousi AM, Qazilbash MH, Popat UR, Gulbis A, Shigle TL, Bassett R, Guillermo-Pacheco M, Ledesma C, Strati P, Ahmed S, Steiner R, Westin J, Nair R, Iyer SP, Champlin RE, Shpall EJ, Andersson BS. High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas. Blood (ASH) 140(Suppl 1):1883-1184, 2022. e-Pub 2022.
90. Agbedia OO, Prakash R, Xu J, Becnel MR, Nair R, Steiner RE, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil LJ, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, Im JS, Fayad L, Jain P, Wang ML, Miranda RN, Vega F, Medeiros J, Oki Y, Flowers CR, Neelapu SS, Iyer SP. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis. Blood (ASH) 140(Suppl 1):2313-2315, 2022. e-Pub 2022.
91. Zoref-Lorenz A, Murakami J, Hofstetter L, Abadi U, Iyer SP, Mohamed SF, Natour AEH, Weinstein S, Yacobovich J, Izrael S, Nikiforow S, Gurion R, Cohen I, Pasvolsky O, Raanani P, Nagler A, Berliner N, Daver N, Ellis MH, Goyal G, Jordan MB. The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation. Blood (ASH) 140(Suppl 1):8326-8328, 2022. e-Pub 2022.
92. Fa K, Prakash R, Sassine J, Handley G, VanWieren T, Angelidakis G, Iyer SP, Ramdial JL, Ahmed S, Nieto Y, Spallone A, Ariza-Heredia EJ, Chemaly R. Cytomegalovirus (CMV) Reactivation within in the First Year after Chimeric Antigen Receptor (CAR) T Cell Therapy: Experience from the First Two Years at a Major Cancer Center. Blood (ASH) 140(Suppl 1):7533-7535, 2022. e-Pub 2022.
93. Nze C, Andersen CR, Ayers A, Westin J, Wang ML, Iyer SP, Ahmed S, Pinnix CC, Vega F, McNeil L, Nguyen L, Nastoupil LJ, Flowers CR. Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution. Blood (ASH) 140(Suopl 1):7943-7945, 2022. e-Pub 2022.
94. Ebinama U, Ai S, Ahmed S, Lee HJ, Liu M, Iyer SP. Risk of Pneumonitis with Immune Checkpoint Inhibitors in Hodgkin's Lymphoma and Other Hematologic Malignancies: A Retrospective Review from Pharmacovigilance. Blood (ASH) 140(Suppl 1):5183-5184, 2022. e-Pub 2022.
95. Aradhya A, Agarwal N, Iyer SP, Huang F, Vega F. Pharmacological Inhibitory Effect of Imetelstat, a Novel Human Telomerase Inhibitor in Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma. Blood (ASH) 140(Suppl 1):11932-11933, 2022. e-Pub 2022.
96. Patel K, Sano D, Maris M, Lesokhin AM, Keudell GV, Doucette K, Ramchandren R, Pavlov D, Uger RA, Molloy N, Bruns I, Scheuber A, Iyer SP. TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology (ASCO) 40(Suppl 16), 2022. e-Pub 2022.
97. Patel K, Sano D, Maris M, Lesokhin AM, Keudell GV, Doucette K, Ramchandren R, Pavlov D, Uger RA, Molloy N, Bruns I, Scheuber A, Iyer SP. TTI-622-01: A phase 1a/1b dose-escalation and expansion trial of TTI-622 in patients with advanced hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL). Journal of Clinical Oncology (ASCO) 40(Suppl 16), 2022. e-Pub 2022.
98. Becnel MR, Horwitz SB, Thomas SK, Iyer SP, Patel KK, Manasanch EE, Weber DM, Kaufman GP, Lee HC, Orlowski RZ. Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
99. Strati P, Mistry H, Pulsifer B, Fayad L, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Dabaja BS, Noorani M, Claussen CM, Shpall E, Kebriaei P, Flowers CR, Westin JR, Neelapu SS. Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
100. Thomas SK, Shah JJ, Morin A, Morphey AN, Lee HC, Manasanch EE, Patel KK, Kaufman GP, Iyer SP, Feng L, Amini B, Qazilbash MH, Bashir Q, Saini N, Srour SA, Johnson RJ, Crumpton BN, Stafford MD, Weber D, Orlowski RZ. Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
101. Patel, Ramchandren R, Maris M, Lesokhin AM, von Keudell GR, Cheson B, Zonder J, Seymour EK, Catalano T, Lin GHY, Uger B, Petrova PS, Roberge K, Shou Y, Iyer SP. Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
102. Srour SA, Xu J, Al-Juhaishi T, Steiner RE, Ensor J, Ahmed S, Parmar S, Strati P, Nastoupil LJ, Nieto Y, Hosing C, Lee JH, Westin J, Fowler NH, Fayad L, Dabaja BS, Pinnix CC, Gunther JR, Fang P, Samaniego F, Jain P, Champlin RE, Khouri IF, Wang M, Miranda RN, Vega F, Neelapu SS, Flowers C, Iyer SP. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
103. Iyer SP, Huen A, Haverkos B, Ai WZ, Okada C, Kuzel TM, Lechowicz MJ, Alderuccio JP, Mohrbacher A, Stevens DA, Wilcox RA, Feldman TA, Sundaram S, Jagadeesh D, Reddy N, Viswanthan-Routhu K, Barde P, Nair AM. A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
104. Horwits SM, O’Connor OA, Pro B, Illidge T, Iyer SP, Advani R, Barlett, NL, Christensen JH, Morschhauser F, Dominto-Domenech E, Rosi G, Kim WS, Feldman TA, Menne T, Belada D, Illes A, Tobani K, Tsukasaki K, S-P Y, Shustov AR, Huttman A, Savage KI, Yuen S, Zinzani PL, Mia H, Bunn V, Fenton K, Fanale MA, Puhlmann M, Truemper L. The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. American Society of Hematology 136(Suppl 1):8-10, 2020. e-Pub 2020.
105. Srour SA, Nieto Y, Iyer SP, Miranda RN, Maadani F, Rondon G, Saini N, Strati P, Daher M, Nair R, Dabaja BS, Popat UR, Qazilbash MH, Shpall EJ, Flowers C, Champlin RE, Hosing C, Khouri IF. Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
106. Khouri IF, Gruschkus SK, Gulbis A, Ledesma C, Jain N, Kadia TM, Pemmaraju N, Anderlini P, Bashir Q, Daher M, Partow K, Marin D, Mehta R, Popat UR, Saini N, Srour SA, Im JS, Fayad L, Nair R, Iyer SP, Strati P, Samaniego F, Nastoupil LJ, Flowers C, Rondon G, Kantarjian HM, Champlin RE, Jabbour E. Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
107. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad L, Lee JH Iyer SP, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego FL, Steiner RE Wang M, Pinnix CC, Flowers C, Sudhakar T, Ramdial J, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
108. Saini N, C-C C, Strati P, Nastoupil LJ, Westin J, Nair R, Fayad L, Ahmed S, Lee JH, Iyer SP, Steiner RE, Greenbaum U, Kebriaei P, Shpall EJ, Jain N, Green MR, Ajami NJ, Flowers C, Champlin RE, Wargo J, Neelapu SS, Jeng RR. Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
109. Zoref-Lorenz A, Murakami J, Hofstetter L, Iyer SP, Alotaibi AS, Miller P, Guber E, Weinstein S, Yacobovich J, Nikiforow S, Ebert BL, Pasvolsky O, Raanani P, Nagler A, Berliner N, Daver N, Ellis MH, Jordan MB. A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
110. Nieto Y, Gruschkus SK, Jones RB, Valdez BE, Timmons M, Hosing C, Anderlini P, Kebriaei P, Pop UR, Qzilbash MH, Alousi AM, Srour SA, Saini N, Ramdial J, Im JS, Shpall EJ, Rezvani K, Gulbis A, Shingle TL, Mahadeo M, Khazal S, Khouri IF, Dabaja BS, Pinnix CC, Gunther JR, Lee H, Ahmed S, Steiner RE, Iyer SP, Nair R, Parmar S, Cuglievan B, Maadani F, Rondon G, Champlin RE, Andersson B. Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. American Society of Hematlology 136(Suppl 1), 2020. e-Pub 2020.
111. Khouri IF, Gruschkus SK, Ledesma C, Anderslin P, Bashir Q, DAher M, Iyer SP, Marin D, Mehta R, Olson AL, Popat UR, Samaniego F, Qazilbash MH, IM JS, Rondon G, Champlin RE, Gulbis A, Young KH. Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. American Journal of Hematology 136(Suppl 1), 2020. e-Pub 2020.
112. Al Hadidi S, Ranjit N, Steiner RE, Ahmed S, Strati P, Parmar S, Iyer SP, Gunther JR, Pinnix CC, Dabaja BS, Nieto Y, Samaniego F, Cuglievan B, Jain P, Fang P, Miranda RN, Medeiros J, Feng L, Chuang H, Wang M, Lee HJ. Association of Epstein–Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin’s Lymphoma. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
113. Khouri IF, Molton DR, Ledesma C, Jabbour E, Rashin Q, Im LS, Fayad L, Lee HL, Nair R, Nastoupil LJ, Samaniego F, Iyer SP, Flowers C, Champlin RE, Sharma P, Gulbis. Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma. American Journal of Hematology 136(Suppl 1), 2020. e-Pub 2020.
114. Strati P, Mistry H, Pulsifer B, Fayad L, Ahmed S, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Dabaja BS, Noorani M, Claussen CM, Shpall E, Kebriaei P, Flowers CR, Westin JR, Neelapu SS. Prognostic Value of Delta Lymphocyte Index (DLIx) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
115. Khouri IF, Gruschkus SK, Gulbis A, Ledesma C, Jain N, Kadia TM, Pemmaraju N, Anderlini P, Bashir Q, Daher M, Partow K, Marin D, Mehta R, Popat UR, Saini N, Srour SA, Im JS, Fayad L, Nair R, Iyer SP, Strati P, Samaniego F, Nastoupil LJ, Flowers C, Rondon G, Kantarjian HM, Champlin RE, Jabbour E. Nonmyeloablative Allogeneic Stem Cell Transplantation with or without Inotuzumab Ozogamicin for Lymphoid Malignancies. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
116. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad L, Lee JH Iyer SP, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego FL, Steiner RE Wang M, Pinnix CC, Flowers C, Sudhakar T, Ramdial J, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
117. Saini N, C-C C, Strati P, Nastoupil LJ, Westin J, Nair R, Fayad L, Ahmed S, Lee JH, Iyer SP, Steiner RE, Greenbaum U, Kebriaei P, Shpall EJ, Jain N, Green MR, Ajami NJ, Flowers C, Champlin RE, Wargo J, Neelapu SS, Jeng RR. Gut Bacterial Diversity Associates with Efficacy of Anti-CD19 CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
118. Zoref-Lorenz A, Murakami J, Hofstetter L, Iyer SP, Alotaibi AS, Miller P, Guber E, Weinstein S, Yacobovich J, Nikiforow S, Ebert BL, Pasvolsky O, Raanani P, Nagler A, Berliner N, Daver N, Ellis MH, Jordan MB. A Novel Inflammatory Index Is Sufficient to Identify Hemophagocytic Lymphohistiocytosis in Adult Patients with Hematologic Malignancies. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
119. Nieto Y, Gruschkus SK, Jones RB, Valdez BE, Timmons M, Hosing C, Anderlini P, Kebriaei P, Pop UR, Qzilbash MH, Alousi AM, Srour SA, Saini N, Ramdial J, Im JS, Shpall EJ, Rezvani K, Gulbis A, Shingle TL, Mahadeo M, Khazal S, Khouri IF, Dabaja BS, Pinnix CC, Gunther JR, Lee H, Ahmed S, Steiner RE, Iyer SP, Nair R, Parmar S, Cuglievan B, Maadani F, Rondon G, Champlin RE, Andersson B. Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. American Society of Hematlology 136(Suppl 1), 2020. e-Pub 2020.
120. Khouri IF, Gruschkus SK, Ledesma C, Anderslin P, Bashir Q, DAher M, Iyer SP, Marin D, Mehta R, Olson AL, Popat UR, Samaniego F, Qazilbash MH, IM JS, Rondon G, Champlin RE, Gulbis A, Young KH. Autologous Vs. Allogeneic Stem Cell Transplantation in Double-Expressor Lymphoma. American Journal of Hematology 136(Suppl 1), 2020. e-Pub 2020.
121. Al Hadidi S, Ranjit N, Steiner RE, Ahmed S, Strati P, Parmar S, Iyer SP, Gunther JR, Pinnix CC, Dabaja BS, Nieto Y, Samaniego F, Cuglievan B, Jain P, Fang P, Miranda RN, Medeiros J, Feng L, Chuang H, Wang M, Lee HJ. Association of Epstein–Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin’s Lymphoma. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
122. Khouri IF, Molton DR, Ledesma C, Jabbour E, Rashin Q, Im LS, Fayad L, Lee HL, Nair R, Nastoupil LJ, Samaniego F, Iyer SP, Flowers C, Champlin RE, Sharma P, Gulbis. Maintenance Therapy with Ipilimumab Plus Lenalidomide after Autologous Stem Cell Transplantation for Patients with Lymphoma. American Journal of Hematology 136(Suppl 1), 2020. e-Pub 2020.
123. Srour SA, Nieto Y, Iyer SP, Miranda RN, Maadani F, Rondon G, Saini N, Strati P, Daher M, Nair R, Dabaja BS, Popat UR, Qazilbash MH, Shpall EJ, Flowers C, Champlin RE, Hosing C, Khouri IF. Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. American Society of Hematology (Blood) 136(Suppl 1), 2020. e-Pub 2020.
124. Thomas SK, Shah JJ, Morin A, Morphey AN, Lee HC, Manasanch EE, Patel KK, Kaufman GP, Iyer SP, Feng L, Amini B, Qazilbash MH, Bashir Q, Saini N, Srour SA, Johnson RJ, Crumpton BN, Stafford MD, Weber D, Orlowski RZ. Update of a Phase II Study of Lenalidomide-Elotuzumab As Maintenance Therapy Post-Autologous Stem Cell Transplant (AuSCT) in Patients (Pts) with Multiple Myeloma (MM). American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
125. Becnel MR, Horwitz SB, Thomas SK, Iyer SP, Patel KK, Manasanch EE, Weber DM, Kaufman GP, Lee HC, Orlowski RZ. Descriptive Analysis of Isatuximab Use Following Prior Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
126. Patel, Ramchandren R, Maris M, Lesokhin AM, von Keudell GR, Cheson B, Zonder J, Seymour EK, Catalano T, Lin GHY, Uger B, Petrova PS, Roberge K, Shou Y, Iyer SP. Investigational CD47-Blocker TTI-622 Shows Single-Agent Activity in Patients with Advanced Relapsed or Refractory Lymphoma: Update from the Ongoing First-in-Human Dose Escalation Study. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
127. Srour SA, Xu J, Al-Juhaishi T, Steiner RE, Ensor J, Ahmed S, Parmar S, Strati P, Nastoupil LJ, Nieto Y, Hosing C, Lee JH, Westin J, Fowler NH, Fayad L, Dabaja BS, Pinnix CC, Gunther JR, Fang P, Samaniego F, Jain P, Champlin RE, Khouri IF, Wang M, Miranda RN, Vega F, Neelapu SS, Flowers C, Iyer SP. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
128. Iyer SP, Huen A, Haverkos B, Ai WZ, Okada C, Kuzel TM, Lechowicz MJ, Alderuccio JP, Mohrbacher A, Stevens DA, Wilcox RA, Feldman TA, Sundaram S, Jagadeesh D, Reddy N, Viswanthan-Routhu K, Barde P, Nair AM. A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma. American Society of Hematology 136(Suppl 1), 2020. e-Pub 2020.
129. Horwits SM, O’Connor OA, Pro B, Illidge T, Iyer SP, Advani R, Barlett, NL, Christensen JH, Morschhauser F, Dominto-Domenech E, Rosi G, Kim WS, Feldman TA, Menne T, Belada D, Illes A, Tobani K, Tsukasaki K, S-P Y, Shustov AR, Huttman A, Savage KI, Yuen S, Zinzani PL, Mia H, Bunn V, Fenton K, Fanale MA, Puhlmann M, Truemper L. The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma. American Society of Hematology 136(Suppl 1):8-10, 2020. e-Pub 2020.
130. Iyer SP, Hunt CR, Pandita TK. Cross Talk between Radiation and Immunotherapy: The Twain Shall Meet. Radiat Res 189(3):219-224, 2018. e-Pub 2018. PMID: 29261410.
131. Nan X, Qin Q, Gentille C, Ensor J, Leveque C, Pingali SR, Phan AT, Rice L, S I. Leukapheresis reduces 4-week mortality in acute myeloid leukemia patients with hyperleukocytosis - a retrospective study from a tertiary center. Leuk Lymphoma 58(9), 2017. e-Pub 2017. PMID: 28140714.
132. Gentille C, Qin Q, Barbieri A, Ravi PS, S I. Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges. Ecancermedicalscience 11, 2017. e-Pub 2017. PMID: 29062389.
133. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SGT, Liu K, SP I, Bearss D, Bhalla KN. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 31(7), 2017. e-Pub 2017. PMID: 28322226.
134. Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, S P, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Study Investigators WWH. Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leuk Lymphoma 58(2), 2017. e-Pub 2017. PMID: 27389174.
135. Devaraj SGT, Rao LGL, Zu Y, Chang JC and Iyer SP. Development of specific DNA aptamers against programmed cell death-1 (Anti-PD1-Apt) for diagnosis and treatment of cancers. Cancer Chemisty 77(13):3243, 2017. e-Pub 2017.
136. Mukherjee A, Nan X, Ensor J, Randhawa JK, Pingali SRK, Zieske AW, Olsen RJ, Chung B and Iyer SP. An Integer Weighted Genomic Mutation Score (GMS) Using Next Generation Sequencing Is Predictive of Prognosis in Intermediate Risk AML Patients. Blood 130(Suppl 1):3940, 2017. e-Pub 2017.
137. Gotur D, Pingali SRK, Rice L, Ibrahim IF, Zimmerman JL, Wong S, Cortes CJ, Puppala M, Z Yin Z, Randhawa JK and Iyer SP. Rothman Index As a Real-Time Predictor of Intensive Care Unit Admissions and Mortality in Acute Myeloid Leukemia Patients Undergoing Induction Chemotherapy. Blood 130(Suppl 1):3444, 2017. e-Pub 2017.
138. Sanchez CG, Qin Q, Sun K, Ensor J, Puppala M, Wong S, Ibrahim IF, Rice L, Iyer SP PSA. Infections in Patients with Myelodysplastic Syndrome. Blood 130(Suppl 1):1694, 2017. e-Pub 2017.
139. Devaraj SGT, Rao LGL, Zu Y, Chang JC, SP I. DNA Aptamer against Anti- Programmed Cell Death-1 (Anti-PD1-Apt) shows robust antileukemia activity in vitro and in vivo human NSG mice with leukemia Xenografts. American Society of Hematology- Session(616), 2017. e-Pub 2017.
140. Bansal H, Kornblau S, Yihua Q, Coombes KR, Panneerdoss S, Karnad A, Weitman S, Tomlinson G, Iyer SP BSA. Overexpression of BRD4 Is an Adverse Prognostic Factor in Acute Myeloid Leukemia. Blood 130(Suppl 1):3794, 2017. e-Pub 2017.
141. Flinn I, Gribben J, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Jones J, SP I, Jones S, Jiang Y, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ. Safety, Efficacy and MRD Negativity of a Combination of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia –Results from a Phase 1b Study (GP28331). Blood(642), 2017. e-Pub 2017.
142. Torres AF, Ramchandren R, Ab Y, Wertheim MS, Edenfield WJ, Caimi P, Gutierrez M, Akard L, Escobar C, Call J, Persky D, SP I, DeMarini DJ, Zhou L, Yeleswaram S and Phillips TJ. Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients With Relapsed or Refractory B-Cell Malignancies (CITADEL- 101). Blood 130(Suppl 1):410, 2017. e-Pub 2017.
143. Torres AF, Ramchandren R, Ab Y, Wertheim MS, Edenfield WJ, Caimi P, Gutierrez M, Akard L, Escobar C, Call J, Persky D, SP I, DeMarini DJ, Zhou L, Yeleswaram S, Phillips TJ. Results from a Phase 1/2 Study of INCB050465, a Highly Selective and Highly Potent PI3Kδ Inhibitor, in Patients With Relapsed or Refractory B-Cell Malignancies (CITADEL- 101). Blood 130(Suppl 1):410, 2017. e-Pub 2017.
144. Bansal H, Kornblau S, Yihua Q, Coombes KR, Panneerdoss S, Karnad A, Weitman S, Tomlinson G, Bansal S, SP I. Overexpression of BRD4 Is an Adverse Prognostic Factor in Acute Myeloid Leukemia. Blood 130(Suppl 1):3794, 2017. e-Pub 2017.
145. Mukherjee A, Nan X, Ensor J, Randhawa JK, Pingali SRK, Zieske AW, Olsen RJ, Chung B, Iyer SP. An Integer Weighted Genomic Mutation Score (GMS) Using Next Generation Sequencing Is Predictive of Prognosis in Intermediate Risk AML Patients. Blood 130(Suppl 1):3940, 2017. e-Pub 2017.
146. Gotur D, Pingali SRK, Rice L, Ibrahim IF, Zimmerman JL, Wong S, Cortes CJ, Puppala M, Z Yin Z, Randhawa JK, Iyer SP. Rothman Index As a Real-Time Predictor of Intensive Care Unit Admissions and Mortality in Acute Myeloid Leukemia Patients Undergoing Induction Chemotherapy. Blood 130(Suppl 1):3444, 2017. e-Pub 2017.
147. Sanchez CG, Qin Q, Sun K, Ensor J, Puppala M, Wong S, Ibrahim IF, Rice L, Pingali SRK, SP I. Infections in Patients with Myelodysplastic Syndrome. Blood 130(Suppl 1):1694, 2017. e-Pub 2017.
148. Lu J, Hou J, Liu KY, Parmar S, De La Fuente A, Andersson B, Yan C, Zhou D, Tan D, Ritchie D, Wu D, Shpall E, Laport GG, Li J, Hu J, Zhang LS, Wang M, Malhotra P, Jiang Q, Qin Y, Wong R, Champlin R, Issaragrisil S, S I, Mathews V, Wang Y, Hu Y, Xiao Z, Shao Z, Rosengarten R, 4th SJ, Xiao JH, Orlowski R, Chim CS. Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China. Leuk Lymphoma 57(7), 2016. e-Pub 2016. PMID: 26887657.
149. Wen J, Tao W, Hao S, SP I, Zu Y. A unique aptamer-drug conjugate for targeted therapy of multiple myeloma. Leukemia 30(4), 2016. e-Pub 2016. PMID: 26242462.
150. Andreeff M, Kelly KR, Yee K, Assouline S, Strair R, Popplewell L, Bowen D, Martinelli G, Drummond MW, Vyas P, Kirschbaum M, SP I, Ruvolo V, González GM, Huang X, Chen G, Graves B, Blotner S, Bridge P, Jukofsky L, Middleton S, Reckner M, Rueger R, Zhi J, Nichols G, Kojima K. Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia. Clin Cancer Res 22(4), 2016. e-Pub 2016. PMID: 26459177.
151. Devaraj SG, Fiskus W, Shah B, Qi J, Sun B, SP I, Sharma S, Bradner JE, Bhalla KN. HEXIM1 induction is mechanistically involved in mediating anti-AML activity of BET protein bromodomain antagonist. Leukemia 30(2), 2016. e-Pub 2016. PMID: 26148704.
152. SP I, Jethava Y, Karanes C, Eckardt JR, and Collins R. Safety Study of Salvage Chemotherapy High-Dose Ara-C/Mitoxantrone (HAM) and Type I FLT3-TKI Crenolanib in First Relapsed/Primary Refractory AML.Acute Myeloid Leukemia: Clinical Studies.Session. Blood 128(22):3983, 2016. e-Pub 2016.
153. Nan X, Greenwood M, Sanchez CG, Xing Y, Zeiski A, Ibrahim I, Baker K, Rice L, Merritt B, Pingali SR, Olsen RJ and Iyer SP. An Integer Weighted Genomic Mutation Scoring (IWGMS) Using the Trusight Myeloid Sequencing Panel (Illumina) Shows Higher Mortality in Patients with Intermediate Risk Acute Myeloid Leukemia- a Retrospective Study. Blood 128(22):2889, 2016. e-Pub 2016.
154. Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, Baetz T, Zelenetz AD, Gaidano G, Fayad LE, Buckstein R, Friedberg JW, Crump M, Jaksic B, Zinzani PL, S PI, Sahin D, Chai A, Fingerle-Rowson G, Press OW. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol 33(30), 2015. e-Pub 2015. PMID: 26282650.
155. Zhao N, Pei SN, Qi J, Zeng Z, SP I, Lin P, Tung CH, Zu Y. Oligonucleotide aptamer-drug conjugates for targeted therapy of acute myeloid leukemia. Biomaterials 67, 2015. e-Pub 2015. PMID: 26204224.
156. SP I, Foss FF. Romidepsin for the Treatment of Peripheral T-Cell Lymphoma. Oncologist 20(9), 2015. e-Pub 2015. PMID: 26099743.
157. Österborg A, Jewell RC, S P, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Furman RR, Robak T, Hillmen P, Trnêný M, Dyer MJ, Piotrowska M, Kozak T, Gupta IV, Phillips JL, Goldstein N, Struemper H, Losic N, Lisby S, Study Investigators WWH. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica 100(8), 2015. e-Pub 2015. PMID: 25769539.
158. Seggewiss-Bernhardt R, Bargou RC, Goh YT, Stewart AK, Spencer A, Alegre A, Bladé J, Ottmann OG, Fernandez-Ibarra C, Lu H, Pain S, Akimov M, SP I. Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma. Cancer 121(13), 2015. e-Pub 2015. PMID: 25809731.
159. Horwitz S, Coiffier B, Foss F, Prince HM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Pinter-Brown L, SP I, Shustov A, Nichols J, Balser J, Balser B, Pro B. Utility of ¹⁸fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26(4), 2015. e-Pub 2015. PMID: 25605745.
160. Cao H, Yin Z, Chen S, Liu T, Liu J, Hu Y, Zhao H, Rice L, Iyer SP and Wong S. Systematic Drug Repositioning By Integrating Transcriptome and Historical Clinical Data, Identification of Digoxin As a Novel Drug Reposition Candidate for High-Risk Myelodysplastic Syndromes. Blood 126(23):4118, 2015. e-Pub 2015.
161. Xinyu N, Pallavi S, Puppala M, Pingali SR, Ibrahim I, Rice L, Phan AT, and Iyer SP. Leukapheresis Reduces 4-Week Mortality in Leukemia Patient with Hyperleukocytosis-a Retrospective Study from a Tertiary Center. Blood 126(23):3782, 2015. e-Pub 2015.
162. SP I, Beck JT, Stewart AK, Shah J, Kelly KR, Isaacs R, Bilic S, Sen S, Munshi NC. A Phase IB multicentre dose-determination study of BHQ880 in combination with anti-myeloma therapy and zoledronic acid in patients with relapsed or refractory multiple myeloma and prior skeletal-related events. Br J Haematol 167(3), 2014. e-Pub 2014. PMID: 25139740.
163. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, SP I, Bearss D, Bhalla KN. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 28(11), 2014. e-Pub 2014. PMID: 24699304.
164. Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, S I, Bradner JE, Bhalla KN. BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther 13(10), 2014. e-Pub 2014. PMID: 25053825.
165. Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT, Zhou X, Danaee H, Liu H, Ecsedy JA, Niu H, Benaim E, Iyer SP. Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs 32(3), 2014. e-Pub 2014. PMID: 24352795.
166. Bansal H, Yihua Q, Iyer SP, Ganapathy S, Proia DA, Penalva LO, Uren PJ, Suresh U, Carew JS, Karnad AB, Weitman S, Tomlinson GE, Rao MK, Kornblau SM, Bansal S. WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia 28(5), 2014. e-Pub 2014. PMID: 24413322.
167. Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, SP I, Bradner JE, Bhalla KN. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther 13(5), 2014. e-Pub 2014. PMID: 24435446.
168. Devaraj SGT, Fiskus W, Shah B, Sharma S, Qi J, Sun B, Saha S, Iyer SP, Zu Y, N Bhalla JBAK. Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells. Blood 124(21):3534, 2014. e-Pub 2014.
169. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, S PI, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol 7:11, 2014. e-Pub 2014. PMID: 24456586.
170. Pro B, Horwitz SM, Prince HM, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Iyer SP, Shustov AR, Wolfson J, Balser BE and Coiffier B. Romidepsin Induces Durable Responses in Patients with Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL). Blood 124(21):1742, 2014. e-Pub 2014.
171. Sun B, Fiskus W, Shah B, Qi J, Devaraj SGT, Iyer SP, Sharma S, Bradner J, Zu Y and Bhalla KN. Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells. Blood 124(21):918, 2014. e-Pub 2014.
172. Yin Z, Konde AS, Puppala M, Srivastava P, Stephen W, Rice L and Iyer SP. Neighborhood Death Rate: A Big-Data Based Health Informatics Pipeline Helps Identify Factors Impacting Clinical Outcomes and Cost Effectiveness in Acute Myeloid Leukemia Patients. Blood 124(21):2625, 2014. e-Pub 2014.
173. Saha S, Fiskus W, Sharma S, Shah B, Rogojina AT, Devaraj SGT, Sun B, Leveque C, Zu Y, Iyer SP and Bhalla KN. Combined Targeting of β-Catenin and FLT-3 Is Synergistically Lethal Against Cultured and Primary AML Blast Progenitor Cells Expressing FLT3 Internal Tandem Duplication (ITD). Blood 124(21):618, 2014. e-Pub 2014.
174. Coiffier B, Radford J, Bosly A, Martinelli G, Verhoef G, Barca G, Davies A, Decaudin D, Gallop-Evans E, S P, Van Eygen K, Wu KL, Gupta IV, Lin TS, Goldstein N, Jewell RC, Winter P, study investigators LS4. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma. Br J Haematol 163(3), 2013. e-Pub 2013. PMID: 24032456.
175. Gojo I, Sadowska M, Walker A, Feldman EJ, SP I, Baer MR, Sausville EA, Lapidus RG, Zhang D, Zhu Y, Jou YM, Poon J, Small K, Bannerji R. Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias. Cancer Chemother Pharmacol 72(4), 2013. e-Pub 2013. PMID: 23949430.
176. Valenta JA, Fiskus W, Manshouri T, Sharma S, Qi J, Schaub LJ, Shah B, Rodriguez M, Devaraj S, Iyer SP, Verstovsek S, Bradner JE and Bhalla KN. Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells. Blood 122(21):2842, 2013. e-Pub 2013.
177. Kelly KR, Persky DO, Mahadevan D, Miller TP, Puvvada SD, McDonagh K, Hayslip J, Park SI, Ruan J, Rosen PJ, SP I, Stefanovic A, Zhang B, Zhou X, Ullmann CD, Leonard EJ and Friedberg JW. Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas. Blood 122(21):3027, 2013. e-Pub 2013.
178. Konde AS, Camposano C, Farah M, Mamta P, Solomon W, Carrum G, John M, Baker KR, Estep J, Bhimraj A, Kamble R, Rice L and Iyer SP. A Retrospective Review Of Factor X Levels and Bleeding Risk In Patients With Amyloidosis. Blood 122(21):3603, 2013. e-Pub 2013.
179. Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, LUMR J, Rodriguez M, Devaraj S, Iyer SP, Bradner JE and Bhalla KN. BRD4 Antagonist and Histone Deacetylase Inhibitor: A Novel Synergistic Combination Against Human Acute Myeloid Leukemia (AML) Cells. Blood 122(21):485, 2013. e-Pub 2013.
180. Nemunaitis J, Mita A, Stephenson J, Mita MM, Sarantopoulos J, S P, Nanda N, Gleich L, Benichou AC, Craig A. Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors. Cancer Chemother Pharmacol 71(1), 2013. e-Pub 2013. PMID: 23053254.
181. Kelly KR, Nawrocki ST, Espitia CM, Zhang M, Yang JJ, S P, Ecsedy J, Giles FJ, Carew JS. Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer 131(11), 2012. e-Pub 2012. PMID: 22488249.
182. Jr BD, Hofmeister CC, S P, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SS. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120(22), 2012. e-Pub 2012. PMID: 23033266.
183. Bansal H, Seifert T, Bachier C, Rao M, Tomlinson G, SP I, Bansal S. The transcription factor Wilms tumor 1 confers resistance in myeloid leukemia cells against the proapoptotic therapeutic agent TRAIL (tumor necrosis factor α-related apoptosis-inducing ligand) by regulating the antiapoptotic protein Bcl-xL. J Biol Chem 287(39), 2012. e-Pub 2012. PMID: 22898820.
184. Kantarjian HM, S P, Stock W, Tallman MS, Curt GA, Li J, Osmukhina A, Wu K, Huszar D, Borthukar G, Faderl S, Garcia-Manero G, Kadia T, Sankhala K, Odenike O, Altman JK, Minden M. Phase I/II multicenter study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4877 in patients with refractory acute myeloid leukemia. Invest New Drugs 30(3), 2012. e-Pub 2012. PMID: 21494838.
185. Parmar S, SP I. Bridging the gap in hematological malignancies. Expert Rev Hematol 5(3), 2012. e-Pub 2012. PMID: 22780206.
186. Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, S P, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol 30(6), 2012. e-Pub 2012. PMID: 22271479.
187. Kelly KR, Espitia CM, Taverna P, Choy G, S P, Nawrocki ST, Giles FJ, Carew JS. Targeting PIM kinase activity significantly augments the efficacy of cytarabine. Br J Haematol 156(1), 2012. e-Pub 2012. PMID: 21689092.
188. Kelly KR, Ecsedy J, Mahalingam D, Nawrocki ST, S P, Giles FJ, Carew JS. Targeting aurora kinases in cancer treatment. Curr Drug Targets 12(14), 2011. e-Pub 2011. PMID: 21777198.
189. Wierda WG, S P, Chan GW, Gupta IV, Lisby S, Study Investigators OAH. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 118(19), 2011. e-Pub 2011. PMID: 21856867.
190. Kelly KR, Ecsedy J, Medina E, Mahalingam D, S P, Nawrocki ST, Giles FJ, Carew JS. The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib. J Cell Mol Med 15(10), 2011. e-Pub 2011. PMID: 21091633.
191. Swords RT, Anguita J, Higgins RA, Yunes AC, Naski M, S P, Kelly KR, Mahalingam D, Philbeck T, Miller L, Puga TA, Giles FJ, Kinney MC, Brenner AJ. A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy. J Clin Pathol 64(9), 2011. e-Pub 2011. PMID: 21606230.
192. Pandya DM, Patel S, Ketchum NS, Pollock BH, S P. A comparison of races and leukemia subtypes among patients in different cancer survivorship phases. Clin Lymphoma Myeloma Leuk(Suppl 1), 2011. e-Pub 2011. PMID: 22035740.
193. Wierda WG, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Mayer J, Smolej L, Hess G, Griniute R, Hernandez-Ilizaliturri FJ, S P, Gorczyca M, Chang CN, Chan G, Gupta I, Nielsen TG, Study Investigators RC4. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 117(24), 2011. e-Pub 2011. PMID: 21498674.
194. Pandya DM, Patel S, Ketchum NS, Pollock BH, S P. A comparison of races and leukemia subtypes among patients in different cancer survivorship phases. Clin Lymphoma Myeloma Leuk(Suppl 1), 2011. e-Pub 2011. PMID: 22035740.
195. Chanan-Khan A, Miller KC, Lawrence D, S P, Miller A, Hernandez-Illatazurri F, Czuczman MS, Wallace PK, Zeldis JB, Lee K. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 117 (10), 2011. e-Pub 2011. PMID: 21523725.
196. Kelly KR, Rowe JH, S P, Nawrocki ST, Carew JS. Mammalian target of rapamycin as a target in hematological malignancies. Target Oncol 6(1), 2011. e-Pub 2011. PMID: 21499765.
197. Wierda WG, Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Hess G, Hernandez-Ilizaliturri FJ, Iyer SP, Fang L, Gorczyca MM, Chan GW, Gupta IV and Lisby S. Correlations Between Ofatumumab Exposure and Treatment Outcomes for Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Ofatumumab, Fludarabine, and Cyclophosphamide Chemoimmunotherapy. Blood 118(21):1793, 2011. e-Pub 2011.
198. Kelly KR, Iyer SP, Goy A, Berdeja JG, Reeder CB, McDonagh KT, Zhou X, Danaee H, Xiao H, Benaim E and Shea TC. Results From a Phase 1 Multicenter Trial of Alisertib (MLN8237)–An Investigational Aurora A Kinase Inhibitor–in Patients with Advanced Hematologic Malignancies. Blood 118(21):2477, 2011. e-Pub 2011.
199. Huff CA, Iyer SP, Kelly KR, Somlo G, Camacho L, Zonder J, Fischer B, Lang L, Zhang S, Gestone T and Bennett KL. A Phase I Study of An Oral Hedgehog Pathway Antagonist, BMS-833923, in Patients with Relapsed or Refractory Multiple Myeloma. Blood 118(21):3993, 2011. e-Pub 2011.
200. Bansal H, Siefert T, Chakravarthy D, Rao M, Tomlinson GE, Sanjay Bansal ISA. Wilm's Tumor 1 Protein Confers TRAIL Resistance in Myeloid Leukemia Cells Through Bcl-Xl. Blood 118(21):2557, 2011. e-Pub 2011.
201. Coiffier B, Pro B, H Prince M, Foss FM, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Iyer S, Shustov AR, Nichols J, Carroll S, Balser J and Horwitz SM. Analysis of Patients with Common Peripheral T-Cell Lymphoma Subtypes From a Phase 2 Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood 118(21):591, 2011. e-Pub 2011.
202. Bansal H, Bansal S, Rao M, Foley KP, Sang J, Proia DA, Blackman RK, Ying W, Barsoum J, Baer MR, Kelly K, Swords R, Tomlinson GE, Battiwalla M, Giles FJ, Lee KP, Padmanabhan S. Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias. Blood 116(22):4591-9, 2010. e-Pub 2010. PMID: 20651072.
203. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, S P, O'Dwyer M, Nawrocki ST, Giles FJ, Carew JS. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 115(18):3796-800, 2010. e-Pub 2010. PMID: 20203261.
204. Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, Robak T, Furman RR, Hillmen P, Trneny M, Dyer MJ, Padmanabhan S, Piotrowska M, Kozak T, Chan G, Davis R, Losic N, Wilms J, Russell CA, Osterborg A, Investigators HS. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 28(10):1749-55, 2010. e-Pub 2010. PMID: 20194866.
205. Ghobrial IM, Hong F, b| PS, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 28(8), 2010. e-Pub 2010. PMID: 20142586.
206. Swords R, Mahalingam D, S P, Carew J, Giles F. Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther 3:89-101, 2009. e-Pub 2009. PMID: 19920925.
207. Chanan-Khan A, Miller KC, Musial L, S P, Yu J, Ailawadhi S, Sher T, Mohr A, Bernstein ZP, Barcos M, Patel M, Iancu D, Lee K, Czuczman MS. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma 50(7):1096-101, 2009. e-Pub 2009. PMID: 19479618.
208. Varadarajan P, Dunford LM, Thomas JA, Brown K, Paplham P, Syta M, Schiff M, S P, Battiwalla M, Smiley S, Hahn T, Jr MP. Seeing what's out of sight: wireless capsule endoscopy's unique ability to visualize and accurately assess the severity of gastrointestinal graft-versus-host-disease. Biol Blood Marrow Transplant 15(5):643-8, 2009. e-Pub 2009. PMID: 19361758.
209. Kelly K, Swords R, Mahalingam D, S P, Giles FJ. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol 4(2):99-105, 2009. e-Pub 2009. PMID: 19381453.
210. Kelly K, Swords R, Kilcoyne A, Sankhala K, Mahalingam D, S P, Giles F. Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow. Leuk Lymphoma 50(2):297-9, 2009. e-Pub 2009. PMID: 19160124.
211. Iyer SP, J Beck J, A Stewart A, J Shah J, K Kelly K, K Anderson K, S Bilic S, LM Chiang LM, A Dzik- Jurasz A, R Isaacs R, M Li M, P Savage P, M Song M, N Munshi N. A Phase I study of BHQ880, a novel osteoblast activating, anti-DKKi human Mab in relapsed and refractory multiple myleloma patients treated with zolendronic acid and anti-myeloma therapy. Blood 114(22):750, 2009. e-Pub 2009.
212. Aggarwal C, Gupta S, Hahn T, Smiley S, S P, Jr MP, Battiwalla M. Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies. Leuk Lymphoma 49(8):1494-500, 2008. e-Pub 2008. PMID: 18766961.
213. S P, Ravella S, Curiel T, Giles F. Current status of therapy for chronic myeloid leukemia: a review of drug development. Future Oncol 4(3):359-77, 2008. e-Pub 2008. PMID: 18518762.
214. Benekli M, Smiley SL, Younis T, Czuczman MS, Hernandez-Ilizaliturri F, Bambach B, Battiwalla M, S P, Jr MP, Hahn T. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone Marrow Transplant 41(7):613-9, 2008. e-Pub 2008. PMID: 18071290.
215. Ailawadhi S, S P. HLA-identical sibling stem-cell transplantation in first-remission AML. Blood 110(13):4619-20, 2007. e-Pub 2007. PMID: 18056849.
216. M1 B, Wu Y, Bajwa RP, Radovic M, Almyroudis NG, Segal BH, Wallace PK, Nakamura R, S P, Hahn T, Jr MP. Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis. Biol Blood Marrow Transplant 13(7):765-70, 2007. e-Pub 2007. PMID: 17580254.
217. Battiwalla M, Wu Y, Bajwa RP, Radovic M, Almyroudis NG, Segal BH, Wallace PK, Nakamura R, S P, Hahn T, Jr MP. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. Biol Blood Marrow Transplant 13(7):765-70, 2007. e-Pub 2007. PMID: 17580254.
218. S P, Battiwalla M, Hahn T, Ball D, Paplham P, Brown K, Segal BH, Jr MP, Almyroudis NG. Two cases of hepatic zygomycosis in allogeneic stem cell transplant recipients and review of literature. Transpl Infect Dis 9(2):148-52, 2007. e-Pub 2007. PMID: 17462002.
219. Reddy N, Karampelas I, Chanan-Khan A, Fenstermaker R, S P. Aggressive relapse of multiple myeloma with intracerebral extension and associated hemorrhage. Leuk Lymphoma 48(6):1228-30, 2007. e-Pub 2007. PMID: 17577791.
220. Chanan-Khan A, Miller KC, Musial L, Lawrence D, S P, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24(34):5343-9, 2006. e-Pub 2006. PMID: 17088571.
221. Miller KC, S P, Dimicelli L, Depaolo D, Landrigan B, Yu J, Doran V, Marshal P, Chanan-Khan A. Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism. Leuk Lymphoma 47(11):2339-43, 2006. e-Pub 2006. PMID: 17107907.
222. Elefante A, Muindi J, West K, Dunford L, Abel S, Paplham P, Brown K, Hahn T, S P, Battiwalla M, McCarthy PL. Long-term stability of a patient-convenient 1 mg/ml suspension of tacrolimus for accurate maintenance of stable therapeutic levels. Bone Marrow Transplant 37(8):781-4, 2006. e-Pub 2006. PMID: 16518428.
223. Battiwalla M, Hahn T, Radovic M, Roy H, Wahab A, Duman E, Bajwa R, S P, Becker J, Barrett AJ, Jr MP. Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. Blood 107(5):1970-3, 2006. e-Pub 2006. PMID: 16282347.
224. Dunford LM, Roy DM, Hahn TE, S P, Segal BH, Almyroudis N, Jr MP, Battiwalla M. Dapsone-induced methemoglobinemia after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 12(2):241-2, 2006. e-Pub 2006. PMID: 16443522.
225. Pawarode A, Baer MR, S P, Wallace PK, Barcos M, Sait SN, Block AW, Wetzler M, Battiwalla M. Simultaneous presentation of acute monoblastic leukemia and mantle cell lymphoma: case report and review of the literature. Leuk Lymphoma 46(12):1813-8, 2005. e-Pub 2005. PMID: 16263586.
226. Raez LE, Cassileth PA, Schlesselman JJ, Sridhar K, S P, Fisher EZ, Baldie PA, Podack ER. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer. J Clin Oncol 22(14):2800-7, 2004. e-Pub 2004. PMID: 15254047.
227. Raez LE, Cassileth PA, Schlesselman JJ, S P, Fisher EZ, Baldie PA, Sridhar K, Podack ER. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Therapy 10(11)(Suppl 1), 2003. e-Pub 2003. PMID: 14605671.
228. Raez LE, Cassileth PA, Schlesselman JJ, S P, Fisher EZ, Baldie PA, Sridhar K, Podack ER. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma. Cancer Gene Therapy 10(11)(Suppl 1), 2003. e-Pub 2003. PMID: 14605671.
229. Maiti A, Daver N, Johnson W, Goyal G, Broome CM, Satyen, Gohil, Laar JV, Lopez Jimenez FJ, Mccall D, Lane H, Kim B, Panicker S, Patou G, Moore S, Mangal B, Covert K, Parry G, Dong K, Dao K, Allen C, Iyer S. ELA026 TARGETING OF SIRP(+) IMMUNE CELLS RESULTS IN A HIGH RESPONSE RATE AND IMPROVED 2- MONTH SURVIVAL OF TREATMENT-NAIVE MALIGNANCY-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS IN A PHASE 1 STUDY. European Hematology Association (EHA).

Books (edited and written)

1. Sathyanarayanan, V, Iyer, SP. The paradigm of early phase studies in hematological malignancies, 2020.

Letters to the Editor

1. Domingo-Domenech, E, Pro, B, Illidge, TM, Horwitz, SM, Trümper, L, Iyer, SP, Advani, RH, Bartlett, NL, Christensen, JH, Kim, WS, Feldman, T, Choi, I, Gritti, G, Belada, D, Shustov, AR, Illés, Á, Zinzani, PL, Hüttmann, A, Trneny, M, Le Gouill, S, Jagadeesh, D, Friedberg, JW, Little, M, Dong, C, Fanale, MA, Fenton, K, Savage, KJ. Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up. Blood cancer journal 15, 2025.
2. Domingo-Domenech, E, Pro, B, Illidge, TM, Horwitz, SM, Trümper, L, Iyer, SP, Advani, RH, Bartlett, NL, Christensen, JH, Kim, WS, Feldman, T, Choi, I, Gritti, G, Belada, D, Shustov, AR, Illés, Á, Zinzani, PL, Hüttmann, A, Trneny, M, Le Gouill, S, Jagadeesh, D, Friedberg, JW, Little, M, Dong, C, Fanale, MA, Fenton, K, Savage, KJ. Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma. Blood cancer journal 15, 2025.

Patents

1. Draft Patent Claims; OTT201522; 10063-024PV1. Patent Number: OTT201522; 10063-024PV1.